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Abstract

Ghrelin, a 28-amino acid peptide, is identified as the endogenous ligand of the
orphan growth hormone secretagogue-receptor type 1a. Ghrelin presents a unique
modification at Ser3 position essential for its activity. It was first discovered in the
stomach of rat in 1999. Aside from ghrelin’s role as a potent growth hormone
secretagogue and food intake modulator, ghrelin is thought to play a role in insulin
and glucagon secretion and in glucose homeostasis. A lot of contradictory data have
been reported in the literature regarding ghrelins co-localization with other hormones
in the islets of Langerhans, its role in insulin secretion and attenuation of type 2
diabetes mellitus. In this study, we investigated the effect of chronic ghrelin
treatment on glucose, body weight and insulin level in normal, STZ-induced diabetic
and ghrelin-treated male Wistar rats. We also examined the distribution pattern and
co-localization of ghrelin in the pancreatic islet of Langerhans with both pancreatic
hormones; insulin and glucagon. In addition, we examined how ghrelin treatment
influences liver function in normal and STZ-diabetic Wistar rats. Control groups
received intraperitoneal injection of normal saline while treated groups received
intraperitoneal injections of 5µg/kg ghrelin on daily basis for duration of four weeks.
Our results show that administration of ghrelin increases the serum insulin level in
both normal and diabetic rats. We also demonstrated that ghrelin co-localizes with
insulin as well as glucagon in the pancreatic islet cells and that the pattern of ghrelin
distribution is shown to alter after the onset of diabetes. Moreover, ghrelin treatment
increased insulin secretion as a result of increasing insulin-secreting β cells. In
conclusion ghrelin co-localizes with both insulin and glucagon in pancreatic islet
cells and plays a regulatory role in insulin secretion.

Keywords: Ghrelin, diabetes mellitus, streptozotocin (STZ), immunohistochemistry
(IHC), liver functions, insulin secretion.
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)Title and Abstract (in Arabic

توزيع الجريلين ) (ghrelinفي خاليا جزر البنكرياس في الجرذان المصابة بالسكري و
السليمة غير المصابة و تأثيره على مرض السكري
الملخص

الجريلين ( )ghrelinهرمون يفرز من المعدة ويتكون من  82حمض أميني ،تم
اكتشافه عام  9111على أنه محفز قوي الفراز هرمون النمو  .يتميز الجريلين بخاصية تعديل
حمضه األميني الثالث سيرين ( )Ser3ليتحول إلى شكله النشط الذي يرتبط بدوره بمستقبالت
افراز هرمون النمو من نوع  )GHS-R 1a( a1ليقوم بلعب دوره في افراز هرمون النمو و
دوره كهرمون منظم للشهية و كافة األنشطة األخرى المعروفة عنه .من جهة أخرى ،يظن
الباحثون أن الجريلين يلعب دور في افراز هرمون االنسولين و الجلوكاجون و أيضا في تعديل
مستويات السكر في الدم.
نظراً الختلف الباحثين بخصوص تأثير الجريلين على افراز هرمون االنسولين وقدرته
على تحسين مرض السكر من النوع الثاني  ،و تعارض نتائج األبحاث حول تواجد الجريلين في
خاليا بيتا المفرزة لالنسولين و خاليا ألفا المفرزة للجلوكاجون في جزر البنكرياس .قمنا
بتصميم هذه الدراسة للبحث عن تأثير العالج بالجريلين على جرذان من نوع  Wistarغير
المصابين بالسكر و مقارنتهم بآخرين تم حقنهم بمادة ستريبتوزوتوسين ( Streptozotocin
” )“STZالتي تستخدم في األبحاث للتسبب بمرض السكر لدى القوارض و غيرها.
كما تمت مقارنة نتائج العالج بالجريلين بنتائج مجموعة أخرى من الجرذان تمت
معالجتهم بمحلول ملحي ( )Normal Salineبعد  4أسابيع من العالج تم خاللها حقن 5
ميكروجرام/كيلوجرام من الجريلين في الصفاق وما يقابلها من المحلول الملحي بشكل يومي.
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يكمن الهدف من هذه األطروحة في الكشف عن دور الجريلين كعالج لمرض السكر،
حيث تقوم الدراسة بعرض تأثير العالج بالجريلين على مستويات السكر بالدم وقدرته على افراز
االنسولين ومدى تأثيره على الوزن نظراً لكونه هرمون فاتح للشهية .كما تمت دراسة تأثير
العالج بالجريلين على وضائف الكبد.
باإلضافة إلى ذلك ،تمت دراسة نمط توزيع الجريلين في جزر البنكرياس وتواجده في
خاليا بيتا المفرزة لهرمون االنسولين و خاليا ألفا المفرزة لهرمون الجلوكاجون.
كشف البحث عن تواجد الجيريلين في خاليا بيتا و ألفا على حد سواء حيث يختلف
التوزيع نسبيا بعد االصابة بمرض السكر .كما أثبتت الدراسة قدرت العالج بالجريلين على
زيادة نسبة االنسولين في الدم؛ كنتيجة لزيادة عدد الخاليا المفرزة لالنسولين في جزر
البنكرياس.

مفاهيم البحث الرئيسية :الجريلين( ،)Ghrelinمرض السكر ،ستريبتوزوتوسين
(” ،)Streptozotocin “STZاختبار المناعه الكيمونسيجية ( Immunohistochemistry
” ،)“IHCوظائف الكبد ،افراز هرمون االنسولين.
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Chapter 1: Introduction

1.1

Pancreas
The word pancreas is derived from Greek word “Pan-Kreas” that means all

flesh. The pancreas is an elongated, soft, J shaped gland. It is light pink in color,
measures approximately 12-15 cm in length and weighs about 70 – 100 g (Tan,
2008). It was the last organ in the abdomen to attract the attention of anatomists,
physiologists, physicians and surgeons.
It is located in the abdominal cavity, in the upper part, behind the stomach
(Figure 1). The Pancreas is divided into 4 parts: head, neck, body and tail (Figure 2).
The head, which is the wider end of the pancreas, lies within the curvature of the
duodenum. The rest of the pancreas lies obliquely in the posterior abdomen, with the
tail extending as far as the gastric surface of the spleen. The neck connects the head
to the main part of the pancreas: the body. The latter is the biggest and main part of
the pancreas located to the left of the superior mesenteric blood vessels. The
superior mesenteric vein joins the splenic vein behind the neck of the pancreas to
form the portal vein (Moore & Dalley, 1999). The pancreas receives it’s blood
supply from the superior and inferior pancreaticoduodenal arteries, while the splenic
artery supplies the tail and part of the body of the pancreas (Figure 3) (Faiz &
Moffat, 2006).
The pancreas is divided into lobules by connective tissue septae (Guyton,
1981). This organ plays a dual role as a secretory gland (Eroschenko, 2008), with
both exocrine and endocrine functions. The exocrine part makes, secretes and
releases digestive enzymes into the duodenum. While, the endocrine part, which is
embedded within the exocrine tissue is responsible for making and secreting a
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variety of pancreatic hormones into the blood stream (Petersen, 1992).

Figure 1: Location of the pancreas.
“Reproduced and edited (Faiz & Moffat, 2006)”.

Figure 2: Structure of the pancreas.
“Reproduced and edited (Faiz & Moffat, 2006)”.
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Figure 3: Pancreatic blood supply and innervations.
“Reproduced and edited (Faiz & Moffat, 2006)”.

1.1.1

Exocrine Part of the Pancreas
The exocrine part is a grape-like cluster of acinar cells which comprises

more than 95% of the pancreas mass. This portion of the pancreas is responsible for
making and secreting the digestive enzymes which are released into the duodenum.
It is composed mainly of acinar and ductal cells with associated connective tissue,
vessels and nerves. The main pancreatic duct is referred to as “Wirsung”, which
begins from the tail and runs to the head of the pancreas to join the common bile
duct to form the hepatopancreatic ampulla (Bockman, Büchler, & Beger, 1986).
The accessory pancreatic duct, which is referred to as the duct of “Santorini” is
superior to the opening of the main duct. The two ducts are responsible for draining
the exocrine secretions through the ampulla of Vater into the duodenum (Campbell
& Verbeke, 2013; Eroschenko, 2008). Digestive enzymes, bicarbonate, NaCl and
water are secreted into the duodenum via pancreatic ducts. These enzymes help in
the digestion of carbohydrates, proteins, and fats and neutralizing stomach acid in
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the duodenum (Ganong, 2005; Pandol, 2011).
1.1.2

Endocrine Part of the Pancreas
Endocrine cells, limited to about 1-2% of the whole pancreatic tissue,

(Barrett, Ghishan, Merchant, Said, & Wood, 2006; Greenstein & Wood, 2011;
Tortora & Derrickson, 2011), regulate pancreatic and gastrointestinal functions and
regulate energy metabolism of the whole-body. The endocrine part is composed
mainly of four types of cells: Alpha (α) (17%), Beta (β) (70%), Delta (δ)(7%) and
PP or Gamma (γ) (Figure 4).
These cells together form what is called the islet of Langerhans, first
described by the German doctor, Paul Langerhans in 1869 (Karamitsos, 2011;
Rosenfeld, 2002a). These cells are richly vascularized and embedded within the
exocrine tissue (Ganong, 2005). Recently, a new cell type termed epsilon (Є) cells
has been discovered in the islets of Langerhans (Ross & Pawlina, 2006). Pancreatic
islet cytoarchitecture differs between species. In rodents, β cells are predominantly
found as a cluster in the core of the islet, while α, δ and γ cells are scattered in the
periphery. On the other hand, human β cells are not clustered and the majority of the
β cells are shown to be scattered in the islet in association with α and δ cells
(Brissova et al., 2005; Cabrera et al., 2006).
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Figure 4: Distribution of pancreatic endocrine cells.
“Modified from Trends Endocrinology and Metabolism, 2012” (Efrat & Russ,
2012).
1.1.3

Hormones of the Pancreas
The endocrine part of the pancreas produces important hormones such as

insulin, glucagon, somatostatin and pancreatic polypeptide, which play a key
regulatory role in several metabolic functions either systemically, regionally (in the
gastrointestinal tract) or locally (in the islet) (Ross & Pawlina, 2006).
1.1.3.1 Insulin
Insulin is a polypeptide hormone composed of 51 amino acids distributed in
2 polypeptide chains, which are linked together by two disulfide bridges [(Figure
5.A); (Harvey & Ferrier, 2011)]. Insulin is the most abundant endocrine polypeptide
(Ross & Pawlina, 2006) and the most well-known pancreatic hormone produced by
β cells (Tan, 2008). Insulin secretion is stimulated by elevated blood glucose level
after a meal or when a person is challenged with glucose (Tortora & Derrickson,
2011).
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1.1.3.1.1 Discovery of Insulin
In 1920, Frederick Banting had the idea that pancreatic digestive enzymes
are harmful to the secretions produced by pancreatic islet of Langerhans. In 1921,
Banting took his theory to Professor John Macleod at the University of Toronto.
Macleod who was a leading figure in diabetes research in Canada provided Banting
with a laboratory, a minimum number of equipment and ten dogs. Charles Best, a
medical student joined Banting to assist him in the experiments which was assigned
to start in the summer of 1921. They removed the pancreas from one dog and
observed that the dog became very weak, thirsty and urinated more often. The dog
blood glucose rose and it had developed diabetes. Using another dog, both Banting
and Best surgically ligated the pancreas to prevent the flow of nourishment which
will result in degeneration of the pancreas. Later on, they isolated the pancreas, froze
it, grinded it and filtered it. When the diabetic dog (first dog) was injected with the
filtered extract, its blood glucose dropped. Its health appeared to be improving and it
was symptoms free with the repetitive administration of the extract, which Banting
and Best called “isletin”. In late 1921, the biochemist, Bertram Collip joined
Banting and Best, and his task was to help in purifying the pancreatic extract so it
can be tested in human. In April, 1922 when Canadian researchers decided on the
name of insulin, which had been proposed by a Belgian doctor a few years prior to
its isolation. Collip succeeded in purifying the extract and it was not until January
1923 when he witnessed the first administration of “insulin” by intramuscular
injected to Leonard Thomson, a 14-year-old boy, who weighed a mere 27 kg. It was
a dramatic moment to see his blood glucose level drop from 440 to 320 mg/dl. The
observation of Leonard’s health after the insulin injection encouraged the team to
introduce the treatment and test it in more diabetic volunteers, who had the same
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response as Leonard to the insulin extract. The Nobel Prize was awarded to Banting
and Macleod on October 26th, 1923. Banting shared his half with Best, while
Macleod split his with Collip (Karamitsos, 2011; Pavel & Sdrobici, 1972; “The
Discovery of Insulin,” n.d.) (Figure 5).

Figure 5: Discoverer of insulin.
From top, J.J.R. Macleod (left), Frederick Banting (right), from bottom, Charles
Best (left) and Bertram Collip (right) (Rosenfeld, 2002b).
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1.1.3.1.2 Synthesis of Insulin
As shown in Figure 6.B, insulin is the end product of an inactive precursor
called preproinsulin. First, “proinsulin” is generated after cleavage of its N-terminal
signal peptide during insertion into the endoplasmic reticulum (ER). Proinsulin
consists of three domains: an N-terminal B chain, a connecting peptide in the middle
known as the C peptide and a C-terminal A chain. Within the ER, proinsulin is
exposed to several specific endopeptidases, which excise the C peptide and so yield
the mature insulin. Finally, the mature form of insulin and the free C-peptide are
packaged in the Golgi apparatus to form secretory granules which accumulate in the
cytoplasm. Since C-peptide and insulin are produced at the same rate, C-peptide is a
useful marker that indicates the effectiveness of insulin production and secretion in
early DM (Harvey & Ferrier, 2011).

Figure 6: Structure and formation of insulin.
Insulin structure (A) and formation from preproinsulin (B) (Harvey & Ferrier,
2011).
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1.1.3.1.3 Function of Insulin
The principal actions of insulin take place in the liver, skeletal muscle and
adipose tissue (Ross & Pawlina, 2006). Insulin lowers the glucose level in the blood
by accelerating the membrane transport of glucose into the liver, muscles cells and
adipose cells. Insulin accelerates the conversion of glucose into glycogen in liver
cells (Eroschenko, 2008). Insulin does not only influence glucose metabolism, but
also plays a role in protein and fat metabolism (Tan, 2008).
1.1.3.1.4 Receptors of Insulin
The insulin receptor, which belongs to the tyrosine kinase superfamily, is a
heterotetrameric glycoprotein that comprises two subunits: α (723 amino acids) and
β (620 amino acids). Alpha subunits exist primarily extracellularly, while β subunits
are transmembrane proteins. Both subunits are connected together with disulfide
bonds (Fig. 7). Binding of insulin molecules to α subunits lead to conformational
changes of the receptors resulting in an autophosphorylation of tyrosine residues by
enabling ATP to bind to the β subunits in the intracellular domain (De Meyts, 2004;
Hubbard, 2013; C. R. Kahn & White, 1988; Kido, Nakae, & Accili, 2001).
Insulin receptors are expressed on virtually all mammalian tissues. The
number of receptors varies from one site to another with nearly more than 200,000
receptors on adipocytes and hepatocytes. The brain was initially thought to be an
insulin-dependent organ. This was based on the awareness that insulin cannot
permeate the blood-brain barrier (C. R. Kahn & White, 1988; Watanabe, Hayasaki,
Tamayama, & Shimada, 1998), but the brain has been shown to have insulin
receptors (Schulingkamp, Pagano, Hung, & Raffa, 2000).
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Figure 7: Insulin receptor.
“Reproduced and edited (Harvey & Ferrier, 2011)”.

1.1.3.1.5 Mechanism of Action of Insulin
Once insulin binds to the α-subunits of the receptor, it provokes many
reactions like the rapid recruitment of insulin-sensitive glucose transporters (GLUT4) into adipocytes and skeletal muscle cells from a pool located in intracellular
vesicles. After the autophosphorylation of β subunits, which in turn phosphorylate
many other proteins such as the insulin receptor substrate proteins (IRS’s). IRS’s,
then activate multiple signaling pathways and lead to many biological effects known
to be exerted by insulin like facilitating the availability of glucose receptors and
correspondingly the ability to uptake glucose molecules (Fig. 8) (Harvey & Ferrier,
2011).
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Figure 8: Mechanism of action of Insulin.
“Reproduced and edited (Harvey & Ferrier, 2011)”.

1.1.3.2 Glucagon
Glucagon is the second most important pancreatic endocrine hormone after
insulin and it is secreted by α cells. Glucagon is usually released in response to low
levels of glucose in the blood (Eroschenko, 2008). Its actions are essentially
reciprocal to those of insulin. For example, it stimulates the release of glucose into
bloodstream, glyconeogensesis and glyconeolysis in liver as well as the proteolysis
to promote gluconeogenesis, mobilizes fats from adipose tissue cells and stimulates
hepatic lipase (Ross & Pawlina, 2006).
1.1.3.3 Somatostatin
Somatostatin, which is produced by δ dells, acts in a paracrine manner to
inhibit insulin and glucagon secretion. Moreover, it plays a role in slowing the
absorption of nutrients from the gastrointestinal tract, gallbladder and inhibiting GH
secretion (Ross & Pawlina, 2006; Tortora & Derrickson, 2011).
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1.1.3.4 Pancreatic Polypeptide
PP cells also known as γ cells secrete a pancreatic polypeptide hormone,
which inhibits somatostatin secretion, gallbladder contraction and secretion of
digestive enzymes by the pancreas (Tortora & Derrickson, 2011). PP has been
implicated in the regulation of energy balance (Asakawa et al., 2003).
1.1.4

Diseases of the Pancreas
Many diseases and disorders have been reported to affect the pancreas. In

addition to developmental anomalies, and trauma, two distinct types of acute and
chronic pancreatitis are the most common conditions along with pancreatic cancer.
The pathogenesis of these disorders is not well established, yet all of them share the
genetic, immunologic and environmental involvement in the manifestation of each
and every one of them. Unfortunately, no cure is available till today. Patient therapy
revolves around pain management and delaying the progression by medication, diet,
endoscopy and surgery (Baker, 2004; Braganza, Lee, McCloy, & McMahon, 2011;
DiMagno & DiMagno, 2012, 2012; Frossard, Steer, & Pastor, 2008, p. -; D. Li, Xie,
Wolff, & Abbruzzese, 2004; Mitchell, Byrne, & Baillie, 2003; Spalding &
Williamson, 2011; Vincent, Herman, Schulick, Hruban, & Goggins, 2011).
Diabetes Mellitus (DM) is one of the major disorders affecting the pancreas.
It attracts a lot of attention because of its complex etiology and its high prevalence
(Section 1.2).
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1.2

Diabetes Mellitus

1.2.1

History of Diabetes Mellitus
The burden of DM has been growing over the years. DM which is becoming

an epidemic disease is not a new phenomenon. DM is thought to have been
described for the first time by an Egyptian called Hesy-Ra, who described a rare
disease which causes loss of body weight, along with a frequent urge to urinate circa
1552 BC.
Aretaeus (30-90CE), the Greek physician was the one who gave diabetes its
name (which in Greek means "flowing through"), when he recorded the symptoms
of constant thirst, frequent urination and loss of body weight. Aretaeus thought it
was a disease of the kidneys. In his book “Causes and Indications of Acute and
Chronic Diseases”, Aretaeus distinguished between DM and diabetes insipidus
(Ahmed, 2002).
In 1025, in the book, “Canon of Medicine”, Avicenna, also known as Ibn
Sina (The famous Arabian Physician) described the symptoms and the complications
of DM in detail.
The term “diabetes” came from the Greek word “diabinein”, which means
“to pass through”, and later, in 1675 the Latin word “mellitus”: i.e. honey-sweet’
was added by the British physician and neuroanatomist, Thomas Willis (Howarth,
2013).
At that same time, an Indian physician called “Charaka Samhita”, identified
diabetes and called it “madhumeha”, which means “honey urine”, when he noticed
that the urine attracts ants and he started to use ants to diagnose his patients with
diabetes. Charaka and another Indian physician called Susruta were the first to
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identify the difference between the two main types of DM, noticing that thin patients
developed diabetes at a younger age compared to obese patients (“dLife Diabetes
Museum,” n.d.).
1.2.2

Epidemiology and Prevalence of Diabetes Mellitus
As the human population’s growth, obesity, sedentary lifestyle, urbanization

and aging increases, the prevalence of DM also increases (Wild, Roglic, Green,
Sicree, & King, 2004). The fast increase of diabetes prevalence and the severity of
its complications are complex challenges that researchers face. A lot of effort is
invested in understanding the complexity of DM and many studies are searching for
ways to cure DM, prevent it or delay its progression.
The sixth edition of the Diabetes Atlas published by the International
Diabetes Federation estimated that, in 2014, 36.8 million people were diagnosed
with DM in the Middle East and North Africa regions (“Diabetes Atlas |
International Diabetes Federation,” n.d.), which corresponds to 9.7% of the
population (Table 1).

Table 1: The prevalence of diabetes mellitus in the Middle East and North Africa.
Modified from International Diabetes Federation, Diabetes Atlas, 6th edition, 2014
(“Diabetes Atlas | International Diabetes Federation,” n.d.).
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Epidemiologists have looked into the prevalence of DM from many aspects,
including the role that geographical location, ethnicity and gender play. Some
reports indicate a higher prevalence of type 1 diabetes mellitus (T1DM) in men,
while type 2 diabetes mellitus (T2DM) was reported to be higher in women.
However, in another study which was conducted in a Mexican population, T2DM
was found to be higher in men than in women. In addition, T1DM was found to be
highest in Scandinavian and lowest in Japanese population (Ernest Adeghate,
Schattner, & Dunn, 2006a).
An unhealthy diet and lack of exercise played a role in listing some of the six
Gulf Cooperation Council Countries among the world’s top 10 countries with the
highest prevalence of DM (Guariguata et al., 2014). DM prevalence is estimated to
be 9% and 25% in Bahrain, 16.1% in Oman, 21.4% in Kuwait, 16.7% in Qatar,
23.7% in Saudi Arabia and 23.3% in the United Arab Emirates(Howarth, 2013).
1.2.3

Definition of Diabetes Mellitus
According to the World Health Organization (WHO) report in 1999, DM is a

metabolic disorder of multiple etiologies, characterized by chronic hyperglycemia
with disturbance in carbohydrate, fat and protein metabolism, which results from
defects in insulin secretion, action or both (“Diagnosis and Classification of
Diabetes Mellitus,” 2010, “WHO | Definition and diagnosis of diabetes mellitus and
intermediate hyperglycaemia,” n.d.).
1.2.4

Classifications of Diabetes Mellitus
DM was previously classified on the basis of insulin dependent treatment,

yet; recently it changed according to the pathology of the disease along with the
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physiological and morphological changes. In literature, T1DM and T2DM are
known to be the main types of DM. Gestational diabetes (GDM) is another common
type of DM which is less prevalent than the other two. Less common classes of DM
include Maturity Onset Diabetes of the Young (MODY), pancreatic DM and others
(See sections 1.2.4.3 & 1.2.4.4).
1.2.4.1 Type 1 Diabetes Mellitus
T1DM was previously called “Insulin Dependent Diabetes Mellitus
(IDDM)” or “juvenile diabetes”; because it occurs in childhood or is young adults.
About 5-10% of cases of DM are T1DM, where the pancreas is either unable
to produce insulin or it does but in very small amounts that do not meet the body’s
need to maintain its function. This may be a consequence of selective pancreatic β
cells autoimmune destruction leading to a crucial decrease in the mass of these cells
in the islets of Langerhans (E. Adeghate, 2001).
The events that trigger the autoimmune response remain unclear. The
pathogenesis of T1DM is known to involve recruitment of CD4+ helper and CD8+
killer T lymphocytes and infiltration of macrophages causing certain interleukins to
attack and destroy pancreatic islets (Gillespie, 2006).
Antibodies against insulin secreting cells, including those against insulin,
glutamic acid decarboxylase and against the whole islet cells are known to be
involved in the development of T1DM pathogenesis (45) and can be detected at
birth or in infancy (Skyler & Sosenko, 2013).
Some researchers suspect a connection between some viruses and T1DM,
especially when alpha interferon was found to be expressed in patients at the onset
of the disease (Scherbaum, 1992). IgM against viruses like Coxsackie was found in
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20 – 30% of patients with T1DM. Likewise, an increase in congenital rubella and
mumps incidences (Ernest Adeghate, Schattner, & Dunn, 2006b), as well as
enterovirus and rotavirus infections (Gillespie, 2006) were consistent with increased
cases of T1DM.
Moreover, patients with T1DM were found to have other autoimmune
disorders such as Addison’s and autoimmune thyroid (Ernest Adeghate et al.,
2006b).
1.2.4.2 Type 2 Diabetes Mellitus
The majority of patients (around 90%) diagnosed with DM have T2DM
which previously was called “Non-Insulin Dependent Diabetes Mellitus (NIDDM)”.
T2DM is characterized mainly by insulin resistance with association of
relatively reduced insulin secretion (S. E. Kahn, 2000; Stumvoll, Goldstein, & van
Haeften, 2005). T2DM predisposition relies on lifestyle and genetics factors(Leahy,
2005). Obesity for instance is the main lifestyle factor which contributes in the
manifestation and development of T2DM (S. E. Kahn, Hull, & Utzschneider, 2006;
Mokdad AH, Ford ES, Bowman BA, & et al, 2003). Other factors known to increase
the risk of developing T2DM are persistent stress and drugs like corticosteroids and
oral contraceptives (Ernest Adeghate et al., 2006b).
1.2.4.3 Gestational Diabetes Mellitus
GDM is another common form of DM known to occur in late gestation and
is characterized by insulin resistance (Ernest Adeghate et al., 2006b). A study done
on Iranian women showed an increased risk of developing GDM in women with
polycystic ovarian syndrome (Ashrafi et al., 2014). Women who develop GDM are
at risk of developing T2DM (Kleinwechter et al., 2014).
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1.2.4.4 Other Types of Diabetes Mellitus
Many cases do not fit into the above classification, yet these cases are
considered to be DM. A specific type of DM may be caused by a mutation in the
insulin receptor and or by genetic impairment of pancreatic β cells, whereas some
may be caused by insufficient insulin release and impaired action. Other cases of
DM may be a consequence of toxin-induced DM. Alzheimer’s disease, caused by
abnormal amyloid protein has been considered by some as the third type of DM
(T3DM) (American Diabetes Association, 2014; Pilcher, 2006).
MODY is another form of DM which is inherited in autosomal dominant
trait. The hyperglycemia appears after puberty and is detectable before the age of
twenty-five years. MODY is treatable without insulin involvement for the first five
years of the onset, yet later on it will require insulin injection like T1DM. MODY
prevalence varies from one population to another. For example it was found that
Blacks and Indian populations have about 10% prevalence, while Caucasians were
found to have less than 1%.
1.2.5

Symptoms of Diabetes Mellitus
Diabetic patients may or may not present characteristic symptoms of

polyuria, continued thirst ‘polydipsia’(Ernest Adeghate et al., 2006b), dramatic loss
of body weight and blurred vision. Without adequate management and treatment
patients will develop a severe form of ketoacidosis or non-ketotic hyperosmolar
state, which will become a life threating condition when it develops to stupor, coma
and eventually death (Figure 9).
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Figure 9: Diabetes mellitus symptoms.
“Reproduced and edited (“diabetes symptoms | Pharma Mirror Magazine,” n.d.)”.
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1.2.6

Criteria for Diagnosis of Diabetes Mellitus
According to the American Diabetes Association (ADA), to diagnose DM

one of the following three measurements should be positive:
1

A fasting plasma glucose (FPG) level ≥126 mg/dL (7.0 mmol/L), or

2

A 2-hour plasma glucose level ≥200 mg/dL (11.1 mmol/L) during a
75 g oral glucose tolerance test (OGTT), or

3

A random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient
with classic symptoms of hyperglycemia and or hyperglycemic
crises

1.2.7

Complications of Diabetes Mellitus
In DM chronic hyperglycemia eventually will cause damage, dysfunction

and failure of various organs like the eyes, kidneys, nerves, heart and blood vessels
(Figure 10). Life-threatening and disabling complications have been also reported,
especially if DM is poorly controlled (“Diagnosis and Classification of Diabetes
Mellitus,” 2010, “WHO | Definition and diagnosis of diabetes mellitus and
intermediate hyperglycaemia,” n.d.).
Complications differ from patient to patient and vary in severity.
Retinopathy, nephropathy, peripheral neuropathy, autonomic neuropathy and sexual
dysfunction are all found among patients with DM. Also incidences of cardiac
complications have been reported to increase in patients with DM. These
complications may be associated with hypertension
Association, 2014).

(American Diabetes
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Figure 10: Diabetes mellitus complications.
“Reproduced and edited (“secondary diabetes mellitus,” n.d.)”.
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A study conducted in Al Ain City, in the United Arab Emirates showed that
the prevalence rates of retinopathy, neuropathy, nephropathy, peripheral vascular
diseases and congestive heart disease were 54.2%, 34.7%, 40.8%, 11.1% and 10.5%,
respectively (Saadi et al., 2007).
Blindness and end-stage renal damage are highly prevalent among patients
with DM. Also poorly controlled DM patients are more susceptible to bacterial and
fungal infections, and developing diabetic foot ulcers (E. Adeghate, 2001).
1.2.8

Management and Treatment of Diabetes Mellitus
There are four main aims of DM treatment. First is to enhance the glycemic

control, second is to slow the progression of the disease, third is to prevent
complications and fourth is to improve quality of life (Shrivastava, Shrivastava, &
Ramasamy, 2013). The aims can be achieved with body weight reduction and active
lifestyle which are considered to be important factors in treating patients with
T2DM, whereas the main corner stone is patient’s compliance to the medications
regimen (Bonora, 2008).
1.2.8.1 Nutrition
A healthy and balanced diet helps in controlling blood sugar level in diabetic
patients. There is no ideal percentage of caloric intakes, typical food plan or eating
pattern that works universally. However individualized nutrition therapy depending
on patient preferences and metabolic goals should be taken into consideration. A
registered dietitian should be assigned to follow up with each and every diabetic
patient; to educate them about their diet and how to approach their glycemic control
goal.
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A gradual and sustained body weight reduction is important for obese
patients with DM or at risk of developing it. It has been shown that body weight
reduction is effective not only in preventing the onset of the disease and its
progression, but also it helps in ameliorating the acute and long-term DM
complications (“REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES
WITH LIFESTYLE INTERVENTION OR METFORMIN,” 2002).
1.2.8.2 Exercise
Many researches in the literature reported that exercise can be a cornerstone
in the management of DM. Lack of exercise among other lifestyle habits like
smoking and alcohol consumption was proven to increase the risk of developing
T2DM (Hu et al., 2001). However, Different types of exercise are effective in DM
management, and physicians should tailor individualized programs for each DM
case depending on the glycemic reading especially for those with T1DM; to meet
their therapeutic goals (Colberg & Swain, 2000).
The role of exercise is not as clear in T1DM as it is in T2DM, and fear of
hypoglycemia and worsening of the complications in T1DM should be taken into
consideration when introducing exercise or any other regular physical activity as one
of the management approaches (Horton, 1988). Increasing insulin sensitivity,
lowering blood glucose level, enhancing lipid profile, reducing the risk for
hypertension and positively affecting the psychological status are well-known
effects of exercise on T2DM, whereas with T1DM the fluctuation between hypoand hyperglycemia can be managed by careful monitoring of blood glucose level,
adjusting insulin doses and following appropriate diet (Riddell & Perkins, 2006;
White & Sherman, 1999).
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1.2.8.3 Pharmacotherapy
In T2DM; Diet, body weight reduction and exercise may not be sufficient to
meet the glycemic control and oral glucose-lowering agents will be introduced to the
patients. T2DM patients might require insulin injection to approach their glycemic
goal; whereas, patients with T1DM depend mainly on insulin for survival.
1.2.8.3.1 Insulin Treatment of Diabetes Mellitus
Insulin is not administered orally because as a peptide hormone it will
rapidly be broken down or digested by the acids in the stomach or by proteolytic
enzyme, respectively; hence insulin is not administered orally. The most common
route of administration for insulin is subcutaneous. Many forms of insulin are
available and it is common practice to use combination therapy of at least two forms
of insulin to treat patients with T1DM.
Insulin forms differ in their origin, onset and duration of action. Aspart,
Lispro and Glulisin are known to be rapid acting insulin with fast onset (15 - 30
minutes), while regular insulin is a short acting type of insulin. Isophane insulin,
insulin zinc suspension and protamine zinc insulin are intermediate acting types of
insulin with onset of action of approximately 1 – 2 hours, while glargine and detemir
are long acting analogues of human insulin (Committee, 2014) (Table 2).
Another form of insulin is Exubera which was approved by the Food and
Drug Administration (FDA) was the first inhaled form of insulin(Wells et al., 2008).
This drug has now been withdrawn because of concerns of developing lung cancer
(Heinemann, 2010) but a new inhalable insulin called Afrezza was approved by the
FDA in June 2014.
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Table 2: Classification of different type of insulin injection according to their
duration of action.
“Reproduced and edited (DiPiro et al., 2011)”

1.2.8.3.2 Oral Antidiabetic Agents
The FDA has approved six classes of antidiabetic agents to treat T2DM; each
class of antidiabetic agent has a different mechanism of action.
1. Insulin secretagogues
1. Sulfonylureas
2. Meglitinide
2. Biguanides
3. Thiazolidinediones (TZD’S) or glitazones
4. Alpha glucosidase inhibitors
5. Other antidiabetic agents
1. Incretin mimetics
2. Dipeptidyl peptidase – IV inhibitors (DPP4)
3. Synthetic amylin analog
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1.2.8.3.2.1 Insulin Secretagogues
Sulfonylureas and meglitinide analogs act by enhancing the release of
insulin. Sulfonylureas differ in potency (second generation agents are more potent),
potential side effects and plasma protein binding affinity. As shown in Figure 11,
sulfonylureas act predominantly through blocking of the ATP-sensitive K+ channel
leading to depolarization of the β cell membrane and Ca2+ influx, resulting in
exocytosis of insulin granules.
Meglitinide analogs like repaglinide, a benzoic acid derivative and
nateglinide, aphenylalanine amino acid derivative are both considered to be short
acting insulin secretagogues. Both necessitate the availability of glucose to exert
their effect, which is similar to sulfonylureas.

Figure 11: Sulfonylureas mechanism of action.
“Reproduced and edited (Katzung, 2007)”.
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1.2.8.3.2.2 Biguanides
Metformin is the only agent available in this class and achieves its action not
by directly acting on β cells but rather by augmenting insulin sensitivity of both
hepatic and peripheral (muscle) tissues leading to increased uptake of glucose
(Figure 12).

Figure 12: Schematic illustration of the mechanism of action of metformin on the
liver cell.
“Reproduced and edited (Rena, Pearson, & Sakamoto, 2013)”
It was shown that pre-gestational use of metformin reduces the risk of
developing GDM (Ashrafi et al., 2014). Metformin has also been used to treat
polycystic ovarian syndrome, which can contribute to GDM (Reyes-Muñoz et al.,
2012; Weerakiet et al., 2004).
1.2.8.3.2.3 Thiazolidinediones or Glitazones
Thiazolidinediones (TZD’s) or glitazones were introduced as a treatment of
T2DM in 1996, when troglitazone was approved by the FDA. Unfortunately
troglitazone was withdrawn from the market due to its side effect (idiosyncratic
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hepatoxicity) in 2000(Kendall, 2006). Other agents such as pioglitazone and
rosiglitazone were approved as treatment for T2DM. Glitazones act by inhibiting
peroxisome proliferator activator receptor γ (PPAR γ) which is located in vascular
and fat cells. This class of drugs enhances insulin sensitivity in muscle, liver as well
as fat tissues and results in increased the level of high density lipoproteins (HDL)
with a slight reduction in blood glucose level. It is a regular clinical procedure to
initially perform a liver function test before start the treatment with any of the
glitazones and to repeat it periodically thereafter.
1.2.8.3.2.4 α-Glucosidase Inhibitors
Acarbose and miglitol, reversibly bind to and inhibit α-glucosidase in the
membrane of the intestinal brush border. Both are taken at the beginning of meals to
exert their effects by delaying the digestion of carbohydrates resulting in lower
postprandial glucose level. They also inhibit pancreatic amylase and interfere with
the breakdown of starch. Since α-glucosidase inhibitors have no effect whatsoever
on insulin secretion and insulin function, it will not result in hypoglycemia if it is
used as a monotherapy. Side effects of this drug may include flatulence, abdominal
cramps and diarrhea, along with complete inhibition of some enzymes such as,
maltase, iso-maltase and glucoamylase which will interfere with absorption of these
nutrients.
1.2.8.3.2.5 Other Antidiabetic Agents
Another two classes of hypoglyceimic agents are the incretin mimetics
(Exenatide) and Dipeptidyl Peptidase–IV Inhibitors (DPP4; Vildagliptin and
Sitagliptin). Both classes improve glucose dependent insulin secretion, they also
slow gastric emptying time, reduce food intake, decrease postprandial glucagon
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secretion and promote β cell proliferation. Exenatide, a 39 amino acid polypeptide,
is 50% homologous to GLP-1, yet unlike GLP-1, increases gastric secretion (Lotfy,
Singh, Kalász, Tekes, & Adeghate, 2011)).
Synthetic Amylin Analog (Pramlintide) is used in the treatment of both
T1DM and T2DM patients (Ernest Adeghate & Kalász, 2011) . Pramlintide exerts
effects similar to those of incretin mimetic agents with the additional favorable
effect of improving satiety (Chapman et al., 2005).
Simultaneous administration of pramlintide and insulin led to 50% reduction
in insulin dose and a reduced risk of hypoglycemia (Clark, Harvey, Finkel, Rey, &
Whalen, 2011; DiPiro et al., 2011; Wells et al., 2008).
1.2.8.4 Surgery
Surgical intervention is usually the last resort for any disease especially if it
is manageable or curable by other approaches. Yet, in DM a surgical approach is
becoming more common and is usually the first choice to either eliminate risk
factors of developing T2DM such as in obese people, or to prevent the progression
of the disease and its complications.
Studies revealed that 83% of patients with T2DM who have undergone
gastric bypass maintained normal blood glucose level and HbA1c concentration
independently from body weight loss. The astonishing remission of T2DM by
gastric bypass is thought to be multifactorial and that gut hormones play a
significant role, especially when a rise in postprandial GLP-1 and peptide YY
concentrations were reported along with reduction in the basal ghrelin level
(Tahrani, Bailey, Del Prato, & Barnett, 2011a, 2011b). It is worth noting, however,
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that gastric bypass surgery has its own shortcomings including the life-long use of
supplements (Padoin et al., 2009)
1.2.8.4.1 Islet and Pancreatic Transplantation
The first known attempt of islet transplantation was reported in 1893
(McCall & Shapiro, 2014), followed by years of trials until success was met
(Robertson, 2004). Moreover, pancreatic transplantation showed persistent success
over the years not only in reducing mortality rates in diabetic patients but also in
ameliorating the complications associated with it (Kelly, Lillehei, Merkel, Idezuki,
& Goetz, 1967).
Patients with T1DM who suffer from a history of severe hyperglycemia and
metabolic instability may receive islet transplantation from multiple donors in
conjunction with immunosuppressive drugs to prevent islet rejection. Islet
transplantation has resulted in insulin independence with exceptional metabolic,
normoglycemia (Warnock et al., 1991) and improved renal function in patients who
received islet cells transplantation alone or in combination with kidney
transplantation (Fiorina et al., 2003).
Patients who are eligible for this procedure mostly have diabetes with endstage renal failure or frequent episodes of hypoglycemia (Gruessner & Sutherland,
2005).
Pancreatic organ transplantation is performed simultaneously with kidney
transplantation with a favor of a living donor for the pancreas if possible; to
maintain the full function of the organ (Farney et al., 2000).
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Post-transplantation complications are common and include organ rejection,
which is the reason behind the lifelong use of immunosuppressive therapy in
patients with organ transplants.
1.2.8.4.2 Other Types of Treatments
There has always been a connection between DM and peptides especially gut
peptides which mainly affect postprandial insulin secretion. These peptides include
incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide 1 (GLP-1) (Ahrén, 2003). Ghrelin which possess an opposite effect to
leptin regarding hunger state (D. E. Cummings, Frayo, Marmonier, Aubert, &
Chapelot, 2004; Higgins, Gueorguiev, & Korbonits, 2007; Hotta et al., 2009), also
plays a role in diabetes especially in T2DM (Katsuki et al., 2004; Østergård et al.,
2003; Pöykkö et al., 2003).
1.2.8.4.3 Glucagon-like Peptide-1
Glucagon-Like Peptide-1 (GLP-1), is a gut-derived incretin hormone known
to stimulate insulin and suppress glucagon. GLP-1 affects food intake and appetite
reversibly. Using incretin enhancers and/or mimetics benefited patients with T2DM
not only due to body weight regulation, but also by reducing fasting and
postprandial blood glucose (Drucker & Nauck, 2006). GLP-1, aside from
stimulating insulin secretion, inhibits glucagon release and regulates glycogen
synthesis in adipose and muscle tissues (Drucker, 1998).
A study where 10 patients were assigned to receive a continuous
subcutaneous infusion of GLP-1 for a period of 6 weeks showed a reduction in
fasting glucose level, HbA1c, fructosamine and free fatty acid and body weight
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along with an increase in insulin sensitivity and improvement in β cell function
(Zander, Madsbad, Madsen, & Holst, 2002).
GLP-1 also inhibits pancreatic β cell apoptosis and enhances proliferation
and differentiation of insulin secreting β cells (Farilla et al., 2003; Perfetti, Zhou,
Doyle, & Egan, 2000; Xu, Stoffers, Habener, & Bonner-Weir, 1999).
1.2.8.4.4 Leptin
Leptin or “satiety hormone”, is produced by fat cells in order to regulate fat
storage in the body. Yet, in obese subjects it was noticed that leptin concentration is
high and correlates to the percentage of body fats (Hickey et al., 1996), which could
be a result of leptin-resistance, in the same manner as insulin resistance (Considine
et al., 1996).
Over the years, a correlation between leptin insufficiency and DM was
studied and reported to account leptin as one of etiological factors in the
pathogenesis of DM, however, with the presence of a feedback regulatory system
between insulin and leptin in regulating glucose homeostasis, leptin was thought to
be the best nominated therapeutic agent to replace insulin injection (B. P.
Cummings, 2013; Kalra, 2013).
1.2.8.4.5 Substance P
Substance P (SP), is a neuropeptide that functions either as a neuromodulator
or neurotransmitter (Datar, Srivastava, Coutinho, & Govil, 2004; Harrison &
Geppetti, 2001). Some reports have shown that SP can reverse diabetes in mice
(Tsui, Razavi, Chan, Yantha, & Dosch, 2007), yet in humans, it decreased insulin
secretion and causes fluctuations in blood glucose level (Brown & Vale, 1976).
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Furthermore, patients with T1DM were found to have low level of serum SP
especially those suffering from diabetic neuropathy (Kunt et al., 2000).
There is contradictory data in the literature about the effect of SP on insulin
secretion. Some studies have reported that a low dose of SP stimulates insulin
release and at a high dose the effect was abolished(Lundquist, Sundler, Ahrén,
Alumets, & Håkanson, 1979), whereas others have shown the effects of SP on
insulin release is dose-dependent (Hermansen, 1980).
1.2.8.4.6 Ghrelin
Ghrelin, a novel peptide was recently discovered and reported to play a role
in insulin secretion (Ernest Adeghate & Ponery, 2004) and thought to influence DM
(Zhang, Zhang, Zhang, Li, & Jiang, 2013) will be further discussed next (section
1.3).
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1.3

Ghrelin

1.3.1

Discovery of Ghrelin
“If one of our team members, Kenji Kangawa, Hiroshi Hosoda, or I, were

not involved, ghrelin would not have been discovered.” said, Masayasu Kojima.
After years of peptide hunting, Kangawa and his team finally succeeded in
discovering a novel peptide named “ghrelin” from a few mg of stomach extract in
1999 (M. Kojima et al., 1999; Masayasu Kojima, 2008; Masayasu Kojima &
Kangawa, 2011).
1.3.2

Structure of Ghrelin
Ghrelin, a word derived from “ghre” which means “grow” in Proto-Indo-

European languages and “relin” which means release (Walker, Gong, Park, Zigman,
& Sakata, 2013) to indicate its role in stimulating growth hormone release (Riley,
Hirano, & Grau, 2002; Takaya et al., 2000). Ghrelin is a 28-amino-acid peptide
secreted by the stomach (from that was termed X/A-like cell in rats and P/D1 cell in
humans) (M. Kojima et al., 1999; Stengel & Taché, 2012), in which Ser3 is
modified by n-octanoic acid which is a unique acyl modification and is essential for
ghrelin’s activity. Ghrelin is encoded in prepro-ghrelin which on splicing yields
three peptides; a single peptide, a mature peptide and a C-terminal peptide (Figure
13) (Sato et al., 2012).
In humans, at least there are four different forms of ghrelin: a non-acylated
form, an n-octanoylated form bound to the serine-3 residue of the peptide, a
decanoylated form, and lastly a decenoylated form (Hiroshi Hosoda, Kojima,
Mizushima, Shimizu, & Kangawa, 2003). N-octanoylated ghrelin is thought to be
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the only active form and exerts different biological effects in different tissues
(Masayasu Kojima, Hosoda, & Kangawa, 2012). However, decanoyl, hexanoyl,
butynoyl and other lipid-modified forms of ghrelin showed some activity (Riley,
2013; Thompson et al., 2004).

Figure 13: Ghrelin synthesis and structure.
“Reproduced and edited (Delporte, 2013)”.

1.3.3

Ghrelin receptor
Ghrelin receptor or growth hormone secretagogue receptor belongs to the G

Protein-coupled receptor family that binds to ghrelin (Howard et al., 2001). In
human, ghrelin receptor is encoded by a single-copy GHSR gene which is located on
chromosome 3 (Wajnrajch, Ten, Gertner, & Leibel, 2011). GHSR gene generates
two isoforms which differ in their carboxyl-terminal, GHS-R1a and GHS-R1b.
GHS-R1a has seven transmembrane domains while GHS-R1b lacks the
transmembrane domains 6 and 7. Isoform 1a is the active receptor which binds
ghrelin and exerts signal transduction in the cell; however, the function of 1b
receptor remains unclear (Gahete et al., 2014; S, 2002; Unniappan & Peter, 2005).
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GHS-R is located in both the central nervous system (CNS) as well as the
peripheral nervous system (PNS). It was found in multi hypothalamic nuclei,
pituitary gland (Reichenbach, Steyn, Sleeman, & Andrews, 2012), in CA2 and CA3
regions of the hippocampus, the substantia nigra, ventral tegmental area, and dorsal
and median raphe nuclei (Davenport et al., 2005). GHS-R is highly expressed in
dopaminergic, cholecystokinin-containing neurons of the substantia nigra and
ventral tegmental area of the midbrain (Zigman, Jones, Lee, Saper, & Elmquist,
2006).
GHS-R was also found to be expressed in the thyroid gland, pancreas,
spleen, myocardium and adrenal gland, stomach, small and large intestines, liver,
lung and adipose tissue, indicating the numerous roles of ghrelin (Gnanapavan et
al., 2002; Masayasu Kojima & Kangawa, 2005).
1.3.4

Tissue Distribution of Ghrelin
Ghrelin is expressed predominantly in the fundus of the stomach (Lee,

Wang, Englander, Kojima, & Greeley, 2002), also in kidney glomerulus (Mori et al.,
2000), intestine (H. Hosoda, Kojima, Matsuo, & Kangawa, 2000), human placenta
(Gualillo et al., 2001) and in human T cells, B cells and neutrophils (Hattori et al.,
2001). Furthermore, ghrelin was detected in human pancreas (Papotti et al., 2000)
where many studies showed ghrelin co-localizes with insulin in β cells (Volante et
al., 2002).Others revealed the presence of ghrelin in α cells indicating its role in
regulating insulin secretion (Yukari Date et al., 2002). However, it was reported that
a new pancreatic cells known as epsilon-cells contain ghrelin (Andralojc et al.,
2009a).
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1.3.5

Ghrelin Signaling Pathway
Ghrelin was found to stimulate the pituitary gland to release GH differently

than GHRH. Binding of ghrelin to its receptor leads to the activation of
phospholipase C1 which in turn leads to an increase in intracellular Ca2+ level via
inositol 1,4,5-triphosphate (IP3) signal transduction and diacylglycerol (Figure 14)
(Malagón et al., 2003).

Figure 14: Signaling pathway of ghrelin-inducing GH release.
“Reproduced and edited (Camiña et al., 2003)”.
The orexigenic effect of ghrelin is mediated by raising [Ca2+]i via adenosine
monophosphate-activated protein kinase (AMPK) in neuropeptide Y (NPY) (Kohno,
Sone, Minokoshi, & Yada, 2008) and agouti-related peptide (AgRP) neurons in the
hypothalamus (Figure 15) (Seoane et al., 2003).
Another way for ghrelin to exert its orexigenic effect is by triggering AMPK
phosphorylation to inhibit mechanistic target of rapamycin complex 1 (mTORC1),
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which is known to have an anorexigenic effect aside from being one of the major
mediators in insulin signaling pathway (Figure 15) (Martin et al., 2007; Veilleux,
Houde, Bellmann, & Marette, 2010).

Figure 15: Signaling pathway of ghrelin-inducing food intake in the hypothalamus.
“Modified from Hindawi Publishing Corporation, Scientifica” (Delporte, 2013)
The vagus nerve was shown to mediate ghrelin effects by transmitting its
signals to the brain (Yukari Date, 2012), aside from ghrelin’s own autocrine,
endocrine and paracrine effects (Avau et al., 2013; De Vriese, Grégoire, De Neef,
Robberecht, & Delporte, 2005; Jeffery, Herington, & Chopin, 2003; Miller et al.,
2005).
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1.3.6

Effect of Ghrelin on Food Intake
Plasma ghrelin level have been shown to increase during fasting and before

meals and decrease after meal, yet in obese humans, ghrelin was not suppressed
after food consumption (English, Ghatei, Malik, Bloom, & Wilding, 2002).
Ghrelin level was also shown to differ dramatically when equal amounts of
calories were served from sugar, protein and fat (Beck, Musse, & Stricker-Krongrad,
2002).
Centrally administered ghrelin led to a significant increase in food
consumption (Lawrence, Snape, Baudoin, & Luckman, 2002) and NPY and AgRP
expression (Goto et al., 2006; Kamegai et al., 2000) independently from its GH
releasing effect (Kamegai et al., 2001; M. Nakazato et al., 2001; M. Tschöp, Smiley,
& Heiman, 2000). Ghrelin also stimulates growth hormone releasing hormone
directly to alter feeding activity (Osterstock et al., 2010).
Ghrelin is thought to play a role in meal initiation (D. E. Cummings et al.,
2001; Sugino et al., 2002), while lacking ghrelin receptor led to less food
consumption (Zigman et al., 2005).
Patients with bulimia nervosa, an eating disorder showed no difference in
ghrelin serum level than the their aged-matched controls (Michiko Nakazato et al.,
2004).
1.3.7

Effect of Ghrelin on Body Weight and Obesity
The dramatic increase in the prevalence of obesity and its consequent

metabolic complications is becoming a burden and a threat to health and life span of
affected individuals or those with a high risk of becoming obese.
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In obese people circulating ghrelin level decrease (Matthias Tschöp et al.,
2001) and correlate negatively with body mass index (BMI) (Shiiya et al., 2002).
Moreover, body weight loss is associated with elevated circulating ghrelin level
(Hansen et al., 2002) implying the possibility of recruiting ghrelin to be used as a
preventive measure to curb the obesity rise.
Whereas, administration of ghrelin caused weight gain (M. Tschöp et al.,
2000), in a dose-dependent manner (Matthias Tschöp, Statnick, Suter, & Heiman,
2002), a study showed that absence of GHS-R1a can protect against developing dietinduced obesity, indicating a direct effect of ghrelin on body weight (Zigman et al.,
2005).
1.3.8

Ghrelin and Pancreatic Islet Cells and its Association with Islet Cells
Hormones
Ghrelin is expressed in pancreatic tissue along with its receptor (Volante et

al., 2002) and interestingly fetal pancreas highly expresses ghrelin than fetal
stomach in the first two weeks postnatal life (Chanoine & Wong, 2004). However,
ghrelin was also found to be secreted from the pancreas (Dezaki et al., 2006).
1.3.8.1 Ghrelin and Insulin
Ghrelin and insulin were found to react correspondingly with preprandial
increase and postprandial decrease (D. E. Cummings et al., 2001; Shiiya et al.,
2002). Moreover, glucose-induced insulin secretion was enhanced by ghrelin
infusion (Takahashi et al., 2006).
In vitro studies have shown that ghrelin induces insulin secretion differently
in normal and in diabetic pancreas (E. Adeghate & Ponery, 2002) and that ghrelin
concentration influences insulin secretion differently (Salehi, Dornonville de la
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Cour, Håkanson, & Lundquist, 2004). In another study, ghrelin failed to stimulate
basal insulin release or to increase cytosolic free calcium concentration in rat β cells
in the presence of 2.8 mmol/l glucose, which is contradictory to its effect at 8.2
mmol/l glucose level (Yukari Date et al., 2002). In a study done by Dezaki K et al,
(2011), ghrelin suppresses glucose-induced insulin release via attenuating cAMP
pathway in β cells (Figure 16) (Dezaki et al., 2011; Wang et al., 2010). Additionally,
ghrelin was found to influence glucose homeostasis through its effect on insulin
secretion and insulin receptor signaling (Yada et al., 2014).

Figure 16: Ghrelin signaling in islet β cells.
“Reproduced and edited (Yada et al., 2014)”.
1.3.8.2

Ghrelin and Other Islets Hormones
Ghrelin co-localized with glucagon in pancreatic α cells (Yukari Date et al.,

2002). However, a study showed that ghrelin is synthesized and secreted from α
cells (Kageyama et al., 2005a). Another study showed that ghrelin induces glucagon
release in diabetic pancreas but not in normal pancreas (Ernest Adeghate & Parvez,
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2002), which might be in part mediated by neuronal constitutive nitric oxide
synthase (Qader, Lundquist, Ekelund, Håkanson, & Salehi, 2005).
Ghrelin was found to significantly increase the circulating levels of both
somatostatin and pancreatic polypeptide in human (Arosio et al., 2003). Whereas,
somatostatin suppresses ghrelin secretion from the stomach (Shimada et al., 2003),
and reduces circulating ghrelin level independently of GH status (Nørrelund et al.,
2002).
1.3.9

Ghrelin Effect on Diabetes Mellitus
Ghrelin was implicated in the development of insulin resistance (Zhang et

al., 2013) and β cell insufficiency (Lin, Chen, Lin, & Duan, 2009) in T2DM
(Pöykkö et al., 2003). Independently from the sedentary life style and obesity,
ghrelin level were found to be reduced in T2DM patients and in insulin-resistant
obese adults (McLaughlin, Abbasi, Lamendola, Frayo, & Cummings, 2004), while
in T2DM women aerobic exercise with the absence of substantial body weight loss
influenced ghrelin level positively (Kadoglou et al., 2012). Furthermore, treatment
of T2DM with metformin raised plasma ghrelin level (Doogue et al., 2009) and
postprandial fall in ghrelin concentrations was prolonged (English et al., 2007).
1.3.10 Other Functions and Role of Ghrelin in Different Tissues
Ghrelin plays a role in many systems (Figure 17). For example, in the
gastrointestinal system, ghrelin acts by increasing gastric acid secretion and
stimulating gastric motility (Y. Date et al., 2001; Masuda et al., 2000). In the
cardiovascular system, ghrelin has potent cardioprotective actions (Nagaya &
Kangawa, 2004) where it plays a role in preventing heart failure (Yang, Liu, Liu, &
Yang, 2014), and associated cardiac dysfunction and remodeling (Du et al.,
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2014).Plasma ghrelin was found to be elevated in advanced renal failure (Tritos,
Kissinger, Manning, & Danias, 2004), yet it decreases significantly in advanced
cancer (Legakis, Stathopoulos, Matzouridis, & Stathopoulos, 2009).
Additionally, ghrelin is thought to be involved in the growth and progression
of tumors (Omoto et al., 2014), whereas ghrelin variants (In1-ghrelin, which lacks
exon 3-4) have been detected in human breast cancer tissue (Gahete et al., 2011).
Ghrelin and ghrelin receptor were also highly expressed in prostate cancer
(Lanfranco et al., 2008).
Ghrelin is involved in many other biological functions like learning (Bellar,
Glickman, Judge, & Gunstad, 2013; E. Li et al., 2013; Tóth, László, & Lénárd,
2010; Zhu et al., 2013), memory (Goshadrou, Kermani, Ronaghi, & Sajjadi, 2013;
Zhao et al., 2014), sleeping (Al-Disi et al., 2010; Figueiro, Plitnick, & Rea, 2012;
García-García, Juárez-Aguilar, Santiago-García, & Cardinali, 2014; Steiger, Dresler,
Schüssler, & Kluge, 2011), depression (Ozsoy, Besirli, Abdulrezzak, & Basturk,
2014; Poretti et al., 2015) and behavior (Carlini et al., 2002; Gastón, Schiöth, De
Barioglio, & Salvatierra, 2015).
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Figure 17: Physiological action of ghrelin.
“Reproduced and edited (Wu & Kral, 2004)”.
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1.4

Streptozotocin and its Diabetogenic Effects
Streptozotocin (STZ) is an antibiotic used in chemotherapy an alkylating

agent in the treatment of metastatic cancer of the pancreatic islet cells. In 1963 it
was reported that STZ is diabetogenic. Ever since STZ has been used by many
researchers to induce experimental models of DM. STZ is known to be particularly
toxic to insulin-secreting β cells in the pancreas. Due its chemical structure which is
similar to glucose, STZ is easily transported into the cell by the glucose transport
protein GLUT2 (Akbarzadeh et al., 2007; Damasceno et al., 2014; Lenzen, 2008;
Szkudelski, 2001).
Figure 18, describes the mechanism of action by which STZ induces DM. In
β cells STZ causes alkylation of DNA which will induce activation of poly ADPribosylation, a process known to be more important for the diabetogenicity of STZ.
Poly ADP-ribosylation leads to cellular NAD+ and ATP depletion which will
provide a substrate for xanthine oxidase resulting in the formation of superoxide
radicals. Consequently, hydrogen peroxide and hydroxyl radicals are also generated.
STZ will also release nitric oxide leading to inhibition of aconitase activity and
finally participates in DNA damage. As a result β cells will be destroyed by necrosis
(Szkudelski, 2001).
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Figure 18: Streptozotocin mechanism in inducing diabetes mellitus.
“Reproduced and edited (Szkudelski, 2001)”.
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Chapter 2: Hypothesis, Aims and Objectives

In literature, ghrelin was not only reported to be expressed in the pancreas
but also to be secreted from it. Based on this we hypothesized that ghrelin colocalizes with insulin-secretin β cells of the pancreatic islet of Langerhans and that it
increases insulin secretion which will result in subsequent low level of glucose in
the blood. We also hypothesized that ghrelin can prevent or delay the onset of DM.
The primary focus of this study was to investigate the effect of ghrelin
treatment on fasting blood glucose, body weight, insulin secretion and liver
functions in normal and STZ-diabetic compared to age-matched control rats. We
also examined the pattern of distribution and co-localization of ghrelin in the
pancreatic islet of Langerhans.
Specific objectives of the study are:
1. To study the effect of chronic ghrelin treatment on fasting blood
glucose level, body weight, glucose handling and insulin secretion in
ghrelin-treated rats in comparison to age-matched controls.
2. To examine the distribution pattern and co-localization of ghrelin
with insulin and glucagon in pancreatic islet cells.
3. To investigate the co-localization of ghrelin and insulin in secretory
granules of β cells.
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Chapter 3: Materials and Methods

3.1

Animal Models
Male Wistar rats aged 7–8 weeks and weighing 200 – 300 g were used in this

study. All rats were acquired from the College of Medicine and Health Sciences,
United Arab Emirates University. Rats were housed in the Animal House Facility
which was maintained at 22-25 °C, along with a 12 hours light/dark cycle. A
standard pellet diet with tap water was provided ad libitum. Diabetic rats were kept
in metal cages and normal (non-diabetic) rats were kept in regular polycarbonate
cages with wood chips bedding.
3.2

Induction of Experimental Diabetes Using Streptozotocin
Streptozotocin (STZ) was used to induce diabetes in rats by a single

intraperitoneal injection at a dose of 60 mg/kg body weight (Akbarzadeh et al.,
2007). STZ was freshly prepared by dissolving it in citrate buffer (0.5M, pH 4.5).
Rats were considered diabetic if their fasting blood glucose level were above 126
mg/dl.
3.3

Experimental Design
As shown in Figure 18, the rats were divided into two groups: normal and

diabetic. Diabetic group received intraperitoneal injection of freshly prepared STZ
(section 2.2) to induce DM. Two days after STZ injection, fasting blood glucose
(FBG) level was measured and rats having FGB level less than 126 mg/dL were
discarded from the study. The two main groups were further subdivided into another
two groups, where one group received normal saline (NS) “as control” and the other
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5 μg/kg body weight of ghrelin “as treated”. Both normal saline and ghrelin were
injected intraperitoneally on a daily basis and for duration of four weeks. At the end
of the fourth week, all rats were sacrificed except some rats from normal treated
group that were subjected to STZ injection to induce diabetes after one week from
stopping ghrelin treatment; in order to investigate the ability of ghrelin to prevent or
delay the onset of DM. FBG and body weight were measured after one week of STZ
injection (Figure 19).

Figure 19: Schematic drawing describing animal groups in this study.
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Figure 20: Schematic drawing explaining the study design of pre-diabetic ghrelintreated group.

3.4

Fasting Blood Glucose and Body Weight Measurements
Body weight was measured once weekly along with FBG level. Animals

were fasted for 12 hours and blood samples were collected from the tail vein in
order to measure FBG using OneTouch® Ultra®2 Glucometer (LifeScan, Inc.,
Milpitas, CA, USA).
3.5

Glucose Tolerance Test
Glucose tolerance test (GTT) was performed at the end of the experiment

(four weeks, except pre-diabetic ghrelin-treated group where it was performed after
six weeks). Rats were fasted overnight (12 hours) and each rat received an
intraperitoneal injection of 10 mg/kg/wt glucose. Blood samples were collected from
the tail vein of the rats and blood glucose level was measured at 0 and 30, 60, 120
minutes after glucose load.
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3.6

Blood and Tissue Collection
After the GTT, all rats were anesthetized with ether. A clean incision through

the abdominal wall was made to expose the organ of interest. Blood was obtained
from the inferior vena cava and kept in two separate tubes (yellow top: gel tube that
helps splitting the serum from the rest of the blood sample components, purple top:
contain EDTA).
Pancreatic tissue was collected from all the animals and cut into two parts:
one part for immunohistochemistry and immunofluorescence studies and the second
for electron microscopy.
3.7

Tissue Processing
Pancreatic tissues were embedded in Zamboni’s fixative for overnight

fixation prior to immunohistochemistry and immunofluorescence studies using light
microscopy. However, for electron microscopy, pancreatic tissues were fixed
overnight in McDowell solution.
3.7.1

Tissue Processing for Immunohistochemistry and Immunofluorescence
Study
After overnight fixation in Zamboni’s fixative pancreatic tissues were

dehydrated in a series of graded ethanol concentrations ascending from 70% to 95%
and “two changes” in 100% ethanol for a minimum of 2 hours per step. Specimens
were then exposed to xylene “two changes” and subsequently paraffin wax at 55 °C
(three changes). Tissues were embedded in paraffin blocks and sections of 6 µm
thickness were sliced using a microtome (Shandon AS325, City, USA), and
incubated in a water bath for a few seconds at 40-42 °C. Tissues were placed on
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gelatin-coated slides, and kept on a hot plate to dry for a minimum of 2 hours to
enhance the attachment of the sections.
3.7.2

Tissue Processing for Electron Microscopy
Some of the pancreatic tissues that were collected at the end of the

experiment, were cut into small pieces, and immersed in McDowell’s fixative for
overnight fixation at 4 °C after trimming off fats and connective tissue. The
specimens were later washed three times with 0.1 phosphate buffer (15 minutes
each) and post-fixed in 1% osmium tetroxide for one hour. The samples were then
dehydrated in ascending concentrations of ethanol (30%, 50%, 70%, 95%, and
100% “two changes”, 15 minutes each). Two changes of propylene oxide was used
for clearing the specimens for 15 minutes each. The samples were then transferred
and exposed to different ratios of propylene oxide and resin (1:1, 1:2 and 1:3) for
one hour each before infiltration with pure resin for overnight at 4 °C. Specimens
were embedded in the resin using molds and kept in the oven to polymerize for
overnight at 60 °C. Blocks of resin were trimmed and 1µm semi-thin sections were
cut using glass knives on the ultra-microtome. Sections were transferred into a drop
of water on the microscope slides using watchmaker’s forceps and toluidine blue
was used to stain the tissues. Toluidine blue-stained tissues were later examined
with the microscope to locate the islets of Langerhans using light microscopy
examination. Using a diamond knife, resin blocks were further trimmed for ultrathin sectioning and placed on copper grids using a wire loop. The girds were placed
on filter paper to dry and left to dry.
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3.8

Immunohistochemistry Study: Avidin-Biotin Complex Staining Method
for Paraffin Section
Pancreatic tissues slides were rinsed for 5 minutes in xylene solution (two

changes) to remove the paraffin wax, followed by rehydration step using a series of
descending concentration of ethanol solution (100% ethanol “two changes, 5
minutes each”, 95%, 70% and 50% “3 minutes each”), followed by washing with
phosphate buffer solution (PBS) for 5 minutes before retrieval of antigen using
citrate buffer (pH 6) treatment, where the slides were incubated for 1 min in the
microwave using power 10, followed by 10 minutes incubation at power 1, and
finally 20 minutes incubation at room temperature. The slides were washed with
PBS (three changes, 5 minutes each) before marking the section with a Dako pen.
Slides were incubated with 0.3% hydrogen peroxidase - methanol solution for 30
minutes to block endogenous peroxidase activity. The tissue sections were blocked
using protein block for 45 minutes at room temperature, followed by overnight
incubation with corresponding primary antibody (insulin anti-guinea pig or ghrelin
anti-rabbit) at 4°C. Next day, the slides were kept at room temperature for an hour
then washed with PBS (three changes, 5 minutes each), followed by incubation with
the secondary biotinylated antibody (anti-guinea pig IgG for insulin and anti-rabbit
IgG for ghrelin) at room temperature for 1 hour. The secondary antibody was
washed off with PBS (three changes, for 5 minutes each), and the section were then
incubated with streptavidin peroxidase conjugated for an hour. To reveal peroxidase
activity, sections were washed with PBS (three changes) for 5 minutes each
followed by 3,3-diaminobenzidine tetrahydrochloride DAB (Sigma) in PBS
incubation at room temperature for 5 minutes.
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Finally, the sections were washed for 5 minutes using distilled water and
dehydrated in a series of ascending concentration of ethanol 50%, 70%, 95% and
100% (two changes) followed by xylene (two changes) for 5 minutes each. The
slides were finally mounted with DPX . AxioCam HRc digital camera with
AxioVision 3.0 software was used to capture images of stained sections (Carl Zeiss,
Oberkochen, Germany). Images were then adjusted for contrast and brightness using
image J 1.47V.
3.9

Double Labeling Immunofluorescence Staining Method for Paraffin
Sections
Sections of pancreas, 6 µm thickness, were immersed twice in xylene for 5

minutes at room temperature to remove paraffin wax followed by rehydration in
descending concentrations of ethanol for 3 minutes each. Slides were then incubated
for 5 minutes in distilled water before treating the slides with citrate buffer for
antigen retrieval in the microwave as described previously in section 2.8. Slides
were then washed three times in PBS after marking the sections of interest with a
Dako pen. Slides were incubated first with the blocking reagent at room temperature
for 45 minutes followed by an overnight incubation with primary antibody (Table 2)
(insulin anti-guinea pig, ghrelin anti-rabbit/ anti mouse and glucagon anti-mouse) at
4 °C. On next day, the slides were incubated at room temperature for one hour
followed by PBS wash (three changes, for 5 minutes each) followed by one hour
incubation at room temperature with the secondary antibody (ghrelin: anti-rabbit /
anti-mouse RRX, insulin: anti-guinea pig FITC and glucagon: anti-mouse FITC)
(Table 3). Finally slides were washed with PBS (three changes, 5 minutes each)
before mounting with CTTI-Fluore mounting media. Slides were examined using a
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fluorescence microscopy. Sections were examined using AxioCam HRc digital
camera with AxioVision 3.0 software (Carl Zeiss, Oberkochen, Germany) fixed with
z-plane fluorescence. Sections contrast and brightness were adjusted images were
merged using image J 1.47V.

Table 3: List of names and dilutions of the primary and secondary antibodies used in
this study
3.10 Transmission Electron Microscopy Post-embedding Immunogold Double
Labeling Protocol
All grids were jet-washed with deionized water (5 mL each), and were
incubated with 25 µL of 10% H2O2 in water for 10 minutes. Grids were again
washed with deionized water and immersed in 0.5 M NH4Cl in 0.01 M PBS (pH 7.3)
for 20 minutes before washing them again with PBS ‘washing buffer’ (1% BSA and
0.1% Tween-20).
Tissues were blocked by 20% normal goat serum (NGS) diluted in washing
buffer ‘blocking buffer’ for 10 minutes followed by overnight incubation at 4 °C
with primary antibody (Ghrelin anti-rabbit 1:100 diluted in PBS, pH 7.3, containing
1% BSA, 0.1% Tween-20 and 5% NGS). Next day, the grids were kept at room
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temperature for an hour before washing them with PBS three times and again
blocking buffer incubation at room temperature for 20 minutes. Grids were further
incubated in goat anti-rabbit IgG conjugated to 15 nm gold particles (diluted 1:20 in
antibody buffer) at room temperature for two hours.
Grids were rinsed again with PBS three times before repeating the whole
process again but with insulin as second primary antibody (insulin anti-mouse
(1:100) diluted in antibody buffer (PBS, pH 7.3, containing 1% BSA, 0.1% Tween20 and 5% NGS)) which was labeled with 5 nm gold particles diluted (1:20 in
antibody buffer) at room temperature for two hours before fixing the grids with
glutaraldehyde (2.5% aqueous) for 5 minutes, then washing with deionized water
and left on filter paper to dry for one hour. Contrasting the grids was done with
uranyl acetate and lead citrate for 15 and 7 minutes, respectively. They were later
washed with deionized water full 10 mL syringes each before leaving the grids to
dry on filter paper. The sections were later viewed with a Philips TEM.
3.11 Enzyme-Linked Immunosorbent Assay
For the quantitative determination of insulin in serum samples, EnzymeLinked

Immunosorbent

Assay

(ELISA)

was

performed

using

Mercodia

Ultrasensitive Rat Insulin ELISA kit and protocol as shown in Figure 21.
In wells 25 μL of Calibrators (standers, 0, ...,6) were added, 25 μL of
samples were added in the rest of the wells followed by the addition of 100 μL of
enzyme conjugate 1X solution into each well, then the plate was incubated in the
shaker (700-900 rpm) for 2 hours at room temperature (18-25°C). Later on, the plate
was wash 6 times with 700 µL wash buffer 1X solution per well using an automatic
plate washer with overflow-wash function. After that a 350 µL washing solution is
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added to each well and discarded. Finally, 200 μL Substrate TMB was added into
each well and was incubate 15 minutes at room temperature (18-25°C) before
adding 50 μL Stop Solution to each well. The plate was placed on the shaker for
approximately 5 seconds to ensure mixing and then the results were read by
Mercodia software using optical density of 450 nm.

Figure 21: Illustration of Mercodia Ultrasensitive Rat Insulin ELISA protocol.
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3.12 Biochemical Analysis
Serum samples was used to detect the levels of Alanine Aminotransferase
(ALT) and Aspartate transaminase (AST) using a Beckman Coulter Synchron Lx20
PRO clinical system at Al Qatara Veterinary Laboratory.
3.13 Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.01. Data
were presented as mean ± Standard Deviation (SD). p<0.05 were considered to be
statistically significant. One-way ANOVA was used between experimental groups
and corresponding control groups, followed by post-hoc Bonferroni. Unpaired t-test
was used to analyze the significance of differences between mean values within the
group between two different time points.
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Chapter 4: Results

4.1

Effect of Ghrelin Treatment on Fasting Blood Glucose Level of Normal

and Diabetic Wistar Rats
Figure 22 shows the effect of ghrelin treatment on fasting blood glucose
level of normal and diabetic rats compared to normal saline treatment in control
groups. Ghrelin treatment did not appear to have an influence on fasting blood
glucose of normal treated rats when compared to normal control. Despite the slight
elevation in fasting blood glucose level of diabetic rats treated with ghrelin after two
weeks from the beginning of the treatment, this group showed lower fasting blood
glucose level when compared to diabetic control group treated with normal saline at
week three and four.

Figure 22: Effect of ghrelin treatment on fasting blood glucose level of normal and
diabetic wistar rats.
Fasting blood glucose level (mg/dL) in normal and diabetic rats treated with either
ghrelin or normal saline (NS), during a course of four weeks treatment. (n=4-7).
Results are expressed as mean ± SD.
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4.2

Effect of Ghrelin Treatment on Body Weight of Normal and Diabetic

Wistar Rats
Figure 23 shows the effect of ghrelin treatment on body weight of normal
and diabetic rats in comparison to age-matched controls treated with normal saline.
After two weeks from the beginning of the treatment, normal and diabetic
groups treated with ghrelin had higher body weight than other rats treated with
normal saline. However, after four weeks, ghrelin-treated rats showed lower body
weight than their corresponding controls.

Figure 23: Effect of ghrelin treatment on body weight of normal and diabetic wistar
rats.
Body weight (g) in normal and diabetic rats treated with either ghrelin or normal
saline (NS), during a course of four weeks treatment. (n=3-7). Results are expressed
as mean ± SD.
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4.3

The Effect of Four Weeks of Ghrelin Treatment on Preventing or

Delaying the Onset of STZ-induced Diabetes Mellitus in Wistar Rats
Figure 24 shows the effect of ghrelin treatment before and after the induction
of DM on fasting blood glucose level and body weight. Body weight (red line) was
increasing upon ghrelin treatment, while fasting blood glucose level (blue line) was
maintained within the normal range. Ghrelin treatment was stopped after four
weeks. The rats received a single intraperitoneal STZ injection to chemically induce
diabetes on week after stopping ghrelin treatment. One week from STZ injection,
body weight showed a significant reduction, whereas fasting blood glucose level
was increased significantly.

Figure 24: The effect of four weeks of ghrelin treatment on preventing or delaying
the onset of STZ-induced diabetes mellitus in wistar rats.
Fasting blood glucose level “mg/dL” (blue line) and body weight “g” (red line) in
normal rats treated with ghrelin before the administration of STZ to chemically
induce DM in the fifth week of the study (arrow). (n=7). Results are expressed as
mean ± SD. (*** P≤0.001)
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4.4

The Effect of Ghrelin Treatment on Glucose Tolerance Test
Figure 25 shows blood glucose values after glucose challenge in normal and

diabetic rats treated with ghrelin compared to age-matched controls treated with
normal saline.
Ghrelin treatment showed no effect on the acute elevation of blood glucose
level in normal group compared to NS treatment in normal control. On the other
hand, though it is not statistically significant (p>0.05), diabetic rats treated with
ghrelin exhibited a slight improvement in responding to glucose challenge when
compared to diabetic rats treated with normal saline at 60 and 120 minutes after
glucose load.
Furthermore, despite the fact that pre-diabetic ghrelin-treated group showed
elevated blood glucose baseline when compared to the other two diabetic groups
which can be explained by the new onset of diabetes, the group handled glucose
challenge well at 120 minutes after glucose loading.

Figure 25: The effect of ghrelin treatment on glucose tolerance test.
Intraperitoneal glucose tolerance in normal and diabetic groups treated with either
ghrelin (before and after diabetes onset) or normal saline (NS), after a course of four
weeks treatment. (n=3-7). Results are expressed as mean ± SD.
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4.5

Summary and Discussion – I


Although it was not statistically significant, but four weeks of ghrelin

treatment succeeded in lowering fasting blood glucose level slightly in diabetic
group.


No differences in the body weight were observed between ghrelin-

treated rats and their age-matched controls treated with normal saline.


Pretreatment of rats with ghrelin did not prevent nor delay the onset

of diabetes mellitus.


Diabetic rats treated with ghrelin whether before or after the onset of

DM showed better glucose handling when compared with diabetic rats treated
with normal saline.
The above outcomes of ghrelin treatment seem promising and might be
enhanced if one (or all) of the parameters of this study changed. For example
increasing the dose of ghrelin for instance can result in either significant reduction
of fasting blood glucose level or in increasing the body weight since many
researches showed that the biological effects of ghrelin are dose-dependent
(Akamizu et al., 2004; Carlini et al., 2002; Saito et al., 2005; ThidarMyint, Yoshida,
Ito, & Kuwayama, 2006). Longer duration of ghrelin treatment may also yield a
better outcome in diabetic rats.
Since it has been reported that pancreatic cells express ghrelin receptor
(Andralojc et al., 2009b; Chanoine & Wong, 2004; Kageyama et al., 2005b) and that
the pancreas can also secrete ghrelin (Dezaki et al., 2006), coupled with the findings
of this study, we decided to further study the pattern of distribution in the rat
pancreas and its association with insulin-secretion cells.
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4.6

Immunohistochemical Localization of Insulin and Ghrelin in Normal

and Diabetic Rat Pancreas
4.6.1

Insulin
Figure 26 shows the distribution pattern of insulin-secreting cells in the

pancreatic tissue of normal control (A), normal treated (B), diabetic control (C)
diabetic treated (D) and pre-diabetic ghrelin-treated (E) rats.
Figure 26 shows insulin-immunopositive cells (black arrows) in the central
and peripheral regions of the islets of normal control rats (A). Whereas in normal
rats treated with ghrelin, this pattern is slightly disrupted (B) and insulinimmunopositive cells (black arrows) are shown to be predominant in the central
region of the islet. In diabetic control group insulin-immunopositive cells are hardly
seen in the islet (C) as a result of STZ selective destruction to insulin-secretin β cells
(Szkudelski, 2001).
On the other hand, a higher number of insulin-immunopositive cells (black
arrows) can be observed randomly in both the center and peripheral regions of islet
in diabetic rats treated with ghrelin before and after the onset of DM, (E) and (D),
respectively.
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4.6.2

Ghrelin
Figure 26 also shows the pattern of distribution of ghrelin-containing cells in

the pancreatic tissue of normal control (F), normal treated (G), diabetic control (H)
diabetic treated (I) and pre-diabetic ghrelin-treated (J) rats.
In normal control rats (F), ghrelin-containing cells (black arrows) are
observed in the central and peripheral regions of pancreatic islets where insulinsecreting cells are usually found.
Whereas, in normal rats treated with ghrelin (G) the distribution pattern of
ghrelin-immunopositive cells (black arrows) was found to be disrupted as insulinimmunopositive cells of the same group (B).
It was noticed that not only the number of insulin-secreting cells are affected
by DM (C), but also the number of ghrelin-containing cells (H) which appear to be
reduced when compared to normal control (F).
Diabetic group treated with ghrelin (I) showed a well preserved distribution
pattern of ghrelin-containing cells (black arrow) in normal control (F). While
ghrelin-immunopositive cells (black arrow) are randomly distributed in the
pancreatic islet of pre-diabetic ghrelin-treated rats which is similar to what was
observed in diabetic control group (H).
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Figure 26: Immunohistochemical localization of insulin and ghrelin in normal and
diabetic rat pancreas.
Distribution pattern of insulin-secreting cells (A, B, C, D, and E) and ghrelinsecreting cells (F, G, H, I, and J) in the pancreatic tissue. Normal control (A and F),
normal treated (B and G), diabetic control (C and H), diabetic treated (D and I) and
pre-diabetic ghrelin-treated (E and J). Arrows shows insulin- and ghrelinimmunopositive cells. Data are typical of those for 4 different animals in each
group. Magnification, X400.
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In order to quantitative the results of ABC staining, both insulin- and
ghrelin-immunopositive cells were counted in correlation to the total number of islet
cells and presented as a percentage, as shown in Figure 27.
In Figure 27-A, the percentage of ghrelin-immunopositive cells is the same
in normal control and normal treated rats. On the other hand, a slight reduction is
noticed in the percentage of ghrelin-immunopositive cells after the onset of DM,
whereas diabetic treated and pre-diabetic treated groups displayed a higher
percentage of ghrelin-positive cells when compared to diabetic control.
The percentage of insulin-immunopositive cells shown in Figure 27-B is
increased in normal treated compared to normal control rats. However, in diabetic
control the percentage of insulin-containing cells showed dramatic reduction
compared to normal control. Moreover, ghrelin treatment in diabetic and prediabetic groups resulted in significant increase in insulin-immunopositive cells, 50%
and 69.3%, respectively, compared to diabetic control.
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Figure 27: Percentage of insulin- and ghrelin-immunopositive cells.
The relative-percentage of ghrelin-immunopositive cells (green bars) and insulinimmunopositive cells (purple bars) in ghrelin treated normal and diabetic groups and
their age-matched controls to total islet cells number. Results are expressed as mean
± SD. * p < 0.006. One-way ANOVA.
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4.7

Summary and Discussion – II


Ghrelin-immunopositive cells in the pancreas share the same

distribution pattern with insulin-secreting cells in normal and diabetic groups.


The distribution pattern of insulin- and ghrelin-containing cells in the

pancreatic islet was shown to be disrupted by the onset of DM in diabetic control
rats and by ghrelin treatment in normal treated rats.


Ghrelin treatment increased the number of insulin-containing cells

significantly in both diabetic and in pre-diabetic groups.


The percentages of insulin- and ghrelin-immunopositive cells in the

pancreatic tissue of diabetic control rats were shown to decrease.
Ghrelin treatment rescued the insulin-secreting cells from STZ selective
destruction in diabetic rats. While in the normal treated group, ghrelin treatment
appears to enhance either the proliferation or the differentiation of insulin-secreting
cells which resulted in a higher percentage of those cells.
Although ghrelin cells in the pancreas (epsilon cells) have been reported to
represent about 1% of total islet cells, our study showed that the percentage of
ghrelin-immunopositive cells is higher in all groups. This indicates that ghrelin is
expressed by other types of cells in the islet. Moreover, inducing DM via STZ
resulted not only in reducing insulin-immunopositive cells but also ghrelinimmunopositive cells which led to the assumption that either epsilon cells are also
sensitive to STZ or that some of the β cells that were destroyed contained both
insulin and ghrelin.
The significant increase in number of insulin-secreting cells observed in this
study has prompted us to perform further experiments to determining serum insulin
level and to examine the co-localization of ghrelin with insulin-secreting cells.
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4.8

Effect of Ghrelin on Serum Insulin Level
Figure 28, shows serum insulin level in normal, diabetic and ghrelin-treated

rats using Mercodia Ultrasensitive Rat Insulin ELISA kit. A clear elevation in serum
level of insulin was observed in all ghrelin-treated groups in comparison to their
corresponding controls. A significant (p <0.02) decrease in serum insulin level of
diabetic control rats was observed when compared to normal control rats.
Furthermore, normal ghrelin-treated rats showed significant (p < 0.04) increase in
insulin level compared to their age-matched control. Moreover, ghrelin treatment
increased serum insulin level in diabetic groups compared to diabetic control;
however it was significant only in pre-diabetic ghrelin-treated group.

Figure 28: Effect of ghrelin on serum insulin level.
Quantitative determination of insulin level in the serum of normal and diabetic
groups treated with either ghrelin (before and after diabetes onset) or normal saline
(NS), for a course of four weeks. (n =4-7). Results are expressed as mean ± S.D. * p
< 0.04 and **p<0.02. Unpaired t-test.
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4.9

Summary and Discussion – III


Ghrelin treatment increased insulin secretion in normal and diabetic

groups of rats.


Despite the new onset of DM in pre-diabetic treated group, ghrelin

pre-treatment showed significant increase in the serum insulin level.
This result suggests that ghrelin treatment did not only increase the
percentage of insulin-secreting cells significantly in diabetic groups (Figure 27) but
also enhanced their secretory function which resulted in increasing serum insulin
level (Figure 28). This suggests that ghrelin treatment rescued β cells from
destruction by STZ.
Moreover, ghrelin treatment impact on insulin secretion can be recruited as a
new approach in DM management to either reduce insulin dose or delay insulin
treatment in T1DM and T2DM, respectively.
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4.9.1

Co-Localization of Ghrelin with Insulin and Glucagon in Pancreatic
Islet Cells

4.9.1.1 Ghrelin and Insulin
Figure 29 shows ghrelin-containing cells (A) and insulin-containing cells (B)
and the co-localization of ghrelin with insulin (C).
It is clearly shown that in normal control rats, ghrelin localizes in both the
central and peripheral portions of the islet where insulin-secreting cells are usually
found. Merging of the two figures shows that ghrelin is co-localized with insulin
(white arrows).
In normal ghrelin-treated group, ghrelin-positive cells are observed to
concentrate in the periphery where glucagon secreting cells are found, however few
cells showed co-localization of ghrelin with insulin.
In diabetic groups, ghrelin-positive cells appear numerous in the pancreatic
islet, in contrast to insulin-positive cells which are observed to be fewer. Moreover,
the distribution pattern of insulin secreting cells is disrupted due to DM. On the
other hand, ghrelin-positive cells localize mainly in the central portion of the
pancreatic islet. On merging, very few cells showed co-localization between ghrelin
and insulin (white arrows).
It is noteworthy that in diabetic and pre-diabetic rats treated with ghrelin,
insulin secreting cells were shown to be increased in number compared to diabetic
control, which resulted in more co-localization between ghrelin and insulin (white
arrows).
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Figure 29: Co-localization of ghrelin with insulin in pancreatic islet cells.
Ghrelin-containing cells (A), Insulin-containing cells (B) and the merged image (C)
where co-localization of ghrelin and insulin (white arrows). Magnification: X 400

74

4.9.1.2 Ghrelin and Glucagon
Figure 30 shows ghrelin-containing cells (A) and glucagon-containing cells
(B) and the co-localization of ghrelin with glucagon (C).
In the pancreatic islet of normal control rats, ghrelin is observed to localize
in the central as well as the peripheral portions, whereas, glucagon is seen primarily
in the peripheral region. On merging, ghrelin was observed to co-localize with
glucagon (white arrow); however, many ghrelin-immunoreative cells do not contain
glucagon.
Moreover, ghrelin was found to concentrate in the periphery of the
pancreatic islet of normal ghrelin-treated group which resulted in a predominant colocalization of ghrelin with glucagon (white arrow).
Figure 30 also shows that ghrelin co-localizes predominantly with glucagon
(white arrow) in diabetic control, diabetic and pre-diabetic treated rats.

75

Figure 30: Co-localization of ghrelin with glucagon in pancreatic islet cells.
Ghrelin-containing cells (A), Insulin-containing cells (B) and the merged image (C)
where co-localization of ghrelin and glucagon (white arrows). Magnification: X 400
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4.9.2

Localization of Ghrelin and Insulin in the Secretory Granules of
Pancreatic β Cells

4.9.2.1 Wistar Normal Control Rat
In Figure 31, shows the localization of ghrelin and insulin in β cells secretory
granules in normal control group.
The majority of secretory granules contain insulin (solid arrow) alone,
whereas ghrelin (dashed arrow) is observed alone in some. Moreover, ghrelin and
insulin where found to share the same secretory granules in normal control
(circle).
Secretory granules
filled with insulin
immuno-gold particle

5 µm
Figure 31: Localization of ghrelin and insulin in the secretory granules of pancreatic
β cells of normal control rats.
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles)
and insulin (5 nm gold particles) in the secretory granules of normal control Wistar
rats. Ghrelin (dashed arrow) and insulin (solid arrow) in the secretory granules
(circle). Magnification: X27500.
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4.9.2.2 Wistar Normal Treated Rat
Figure 32, shows the localization of ghrelin and insulin in β cells secretory
granules in normal ghrelin-treated group.
Most of the secretory granules of pancreatic β cells contain ghrelin (dashed
arrow) in contrast to normal control group (Figure 31). Furthermore, many secretory
granules are found to contain both ghrelin and insulin (circle).

Secretory granules
filled with ghrelin
immuno-gold particle

5 µm
Figure 32: Localization of ghrelin and insulin in the secretory granules of pancreatic
β cells of normal ghrelin-treated rats.
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles)
and insulin (5 nm gold particles) in the secretory granules of normal Wistar rats
treated with ghrelin. Ghrelin (dashed arrow) and insulin (solid arrow) in the
secretory granules (circle). Magnification: X27500.
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4.9.2.3 Wistar Diabetic Control Rat
Figure 33 shows the localization of ghrelin and insulin in β cells secretory
granules in diabetic control group.
In diabetic control group, the secretory granules can be seen to reduce in
number in diabetic control in comparison to normal control (31) as well as insulinimmunopositive gold-conjugates (solid arrow). In addition, ghrelin (dashed arrow)
was found to co-localize with insulin in some of the secretory granules (circle).

5 µm
Figure 33: Localization of ghrelin and insulin in the secretory granules of pancreatic
β cells of diabetic control rats.
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles)
and insulin (5 nm gold particles) in the secretory granules of untreated diabetic rats.
Ghrelin (dashed arrow) and insulin (solid arrow) in the secretory granules (circle).
Magnification: X27500.
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4.9.2.4 Wistar Diabetic Treated Rat
Figure 34 shows the localization of ghrelin and insulin in β cells secretory
granules in diabetic group treated with ghrelin.
Ghrelin treatment resulted in increasing both ghrelin (dashed arrow) and
insulin (solid arrow) in the diabetic group compared to their age-matched control
(Figure 33). Moreover, ghrelin immunopositive gold-conjugates are seen to share
secretory granules in pancreatic β cells with insulin (circle).

Secretory granules filled
with ghrelin immunogold particle

5 µm
Figure 34: Localization of ghrelin and insulin in the secretory granules of pancreatic
β cells of diabetic ghrelin-treated rats.
Electron micrograph showing immunogold labeling of ghrelin (15 nm gold particles)
and insulin (5 nm gold particles) in the secretory granules of diabetic rats treated
with ghrelin. Ghrelin (dashed arrow) and insulin (solid arrow) in the secretory
granules (circle). Magnification: X27500.
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4.10 Summary and Discussion – IV


This study showed that ghrelin co-localizes with both insulin and

glucagon.


We revealed that ghrelin co-localization pattern is disrupted after the

onset of DM (diabetic control).


We demonstrated that ghrelin co-localizes with insulin in the

secretory granules of pancreatic β cells.
Investigating the co-localization of ghrelin and insulin in secretory granules
of pancreatic β cells revealed that in ghrelin-treated groups both ghrelin and insulin
immunopositive gold-conjugates were observed to be higher when compared to agematched controls.
Furthermore, in ghrelin-treated group many secretory granules contain both
ghrelin and insulin; whereas in normal and diabetic control groups few secretory
granules were shown to contain both of them together.
In addition, a previous study (Kageyama et al., 2005c) showed that GHS-R
localizes with glucagon in the periphery of the islet. Also the same study showed
that both ghrelin and GHS-R are located in the periphery of the pancreatic islets
where glucagon cells are found. Along with the outcomes of this study, we
concluded that ghrelin may enhance insulin secretion directly and also indirect
through either inhibiting the effect of glucagon or by inhibiting its secretion.
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4.11 Effect of Ghrelin Treatment on Liver Function
4.11.1 Alanine Transaminase
Figure 35, shows serum Alanine Transaminase (ALT) level in normal,
diabetic and ghrelin-treated groups.
The serum ALT level was elevated in control and ghrelin-treated groups.
However, in diabetic groups treated with ghrelin, ALT level was further elevated.
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Figure 35: Serum Alanine Transaminase levels.
Serum ALT level of normal, diabetic and ghrelin-treated rats (ref. range: 17.5 – 30.2
IU/l). (n=3-7).
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4.11.2 Aspartate Transaminase
Figure 36, shows serum Aspartate Transaminase (AST) level in normal,
diabetic and ghrelin-treated groups.
Serum AST level was also elevated in control groups as well as ghrelintreated groups. However AST level was higher in diabetic groups treated with
ghrelin.
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Figure 36: Serum Aspartate Transaminase levels.
Serum AST level of normal, diabetic and ghrelin-treated rats (ref. range: 45.7-80.8
IU/l). (n=3-7).
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4.12 Summary and Discussion – VII
In this study we tried to determine the effect of ghrelin chronic treatment on
liver function by measuring the level of Alanine Transaminase (ALT) and AST in
the blood serum of normal, diabetic and ghrelin-treated rats.
ALT and AST are enzymes mainly found in liver, but also in small amount
in the heart, pancreas, muscle and kidneys. Elevated level of ALT or AST or both
indicates presence of liver damage.
Control and ghrelin-treated groups showed elevated serum levels of ALT and
AST. However, ghrelin treatment and pre-treatment in diabetic rats resulted in much
higher levels of both enzymes than any other group which indicates liver damage.
Our results of the harmful effect of ghrelin on liver correlate with De Vriese
et al, who suggested the involvement of ghrelin in the pathogenesis of liver diseases
(Delhanty & van der Lely, 2013; Estep et al., 2011; Mykhalchyshyn, Kobyliak, &
Bodnar, 2015).Furthermore, ghrelin was reported to modulate liver function
(Okamatsu et al., 2009).
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Chapter 5: Summary

Figure 37: Summary of the outcomes in this study.
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Chapter 6: Discussion


Maintenance of glucose homeostasis is a very complicated process.

Many neuroendocrine hormones are involved in regulating glucose uptake,
storage and release.


Our results imply that ghrelin has an important role in glucose

homeostasis which correspond to Heppner KM et al, report (Heppner, Müller,
Tong, & Tschöp, 2012). However, the controversy about the exact effects of
ghrelin on blood glucose level remain unresolved (Chabot, Caron, Laplante, &
St-Pierre, 2014).


In literature, it was reported that ghrelin level correlates positively

with insulin resistance (Purnell, Weigle, Breen, & Cummings, 2003). However
Pöykkö SM et al, reported that in T2DM ghrelin concentration was negatively
associated with insulin resistance (Pöykkö et al., 2003). However, in this study
ghrelin-treated rats handled glucose challenge well indicating that ghrelin
enhances tissues response to insulin.


Ghrelin is known as a “hunger hormone” (Higgins et al., 2007) and

was reported to increase food consumption (Kamegai et al., 2001). Moreover,
while many studies showed that ghrelin treatment positively induces weight gain
(Salfen, Carroll, Keisler, & Strauch, 2004), a study on Japanese quail showed
that the effect of ghrelin on food intake correlates negatively with the dose of
ghrelin (Shousha et al., 2005). However our observation correlates with those of
Gelling RW et al, which revealed that food intake of STZ-diabetic rats was
increased despite their weight reduction (Gelling et al., 2004). Unfortunately, no

86

measurement was taken to calculate the food consumption in this study and the
reasons behind the slight reduction in the body weight are not clear.


Altering one or two or all of the treatment criteria such as dose,

duration and frequency of the treatment, may further influence our outcomes.
Moreover, the difference between our results and those available in the literature
may be due to one of more of the factors outlined above.


We have demonstrated that the distribution pattern of ghrelin-

containing cells is similar to that of insulin-containing cells and that both
patterns were disrupted after the onset of DM. Moreover, in a study investigating
the cellular distribution of ghrelin in the pancreas of diabetic rats it was shown
that DM is associated with a slight reduction in the expression of ghrelin in
pancreatic islet cells (Yildirim, Sundler, & Bolkent, 2007). This observation
corroborates data reported in our study.


We also revealed that ghrelin treatment and pre-treatment resulted in

significant increase of insulin-containing cells. This finding is in agreement of
that of Turk et al., who reported that the number of insulin-positive cells
increase after the administration of 100 µg of ghrelin per day for four weeks
(Turk, Dağistanli, Sacan, Yanardag, & Bolkent, 2012).


Moreover, ghrelin treatment resulted in elevated level of serum

insulin, indicating the role of ghrelin in enhancing insulin secretion. This
suggests the possibility of recruiting ghrelin as a potential therapeutic approach
in the management of DM.


Additionally, ghrelin was observed to co-localize with both insulin

and glucagon in pancreatic islet. The co-localization of ghrelin with insulin was
disrupted in diabetic control group and in normal ghrelin-treated group.
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However, ghrelin and glucagon co-localization was not affected in either
diabetic control or normal ghrelin-treated groups. Ghrelin localization in
pancreatic islet cells is controversial. Our observation implies that ghrelin
predominantly co-localizes with glucagon in pancreatic islet, which corroborates
with those of Date, et al. (Yukari Date et al., 2002), who showed that ghrelin is
located in pancreatic α cells. However, another studies revealed that ghrelin colocalizes with β cells (Volante et al., 2002), while some have even reported that
ghrelin has its own cells (Wierup, Yang, McEvilly, Mulder, & Sundler, 2004).


Furthermore, our study demonstrated that ghrelin co-localizes with

insulin in the secretory granules of pancreatic β.


Elevated serum levels of AST and ALT indicates liver injury (Nkosi,

Opoku, & Terblanche, 2006; Senior, 2012). Moreover, it is known that the
serum level of ALT increases after the onset of diabetes (Aragon & Younossi,
2010). Our investigation of ghrelin effect on liver function revealed that in DM,
ghrelin treatment increase AST and ALT enzymes indicating that ghrelin may be
involved in the pathogenesis of liver injury.
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Chapter 7: Conclusion

We addressed our hypothesis and demonstrated that ghrelin co-localizes with
insulin-secreting β cells. We also revealed the involvement of ghrelin in insulin
secretion and its effect on lowering blood glucose level. Unfortunately, ghrelin
failed to prevent/delay DM which was the second hypothesis of this study.
The outcomes of this investigation suggest that ghrelin can be a new
approach in DM management (Figure 38).

Figure 38: Conclusion of the study
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Chapter 8: Limitations and Future Prospective


The number of rats was low in some groups which resulted in higher

Standard Deviation.


The duration of treatment was only four weeks and we studied only

one dose, which is considered to be relatively low.


Our data represents the effect of ghrelin treatment in only one model

of DM (T1DM).


We only studied the co-localization of ghrelin with insulin in

pancreatic β cells secretory granules. The study of the co-localization of ghrelin
with glucagon in the secretory granules of α cells is the next step; to address
whether ghrelin influence on insulin secretion is a result of ghrelin hypothesized
effect on glucagon secretion/inhibitory effect on insulin, in addition to
measuring glucagon level in blood serum.


Studying the effect of ghrelin treatment at a younger age (birth!).



Determining the amount of food consumption and examining the

effect of ghrelin on different caloric intake.


Finally, more investigations are required to examine the reason

behind the slight reduction in body weight by studying the possibility of
feedback inhibition via measuring circulating ghrelin level.

90

Bibliography
Adeghate, E. (2001). Diabetes mellitus - multifactorial in aetiology and global in
prevalence. Archives of Physiology and Biochemistry, 109(3), 197–199.
http://doi.org/10.1076/apab.109.3.197.11588
Adeghate, E., & Kalász, H. (2011). Amylin analogues in the treatment of diabetes
mellitus: medicinal chemistry and structural basis of its function. The Open
Medicinal Chemistry Journal, 5(Suppl 2), 78–81.
http://doi.org/10.2174/1874104501105010078
Adeghate, E., & Parvez, H. (2002). Mechanism of ghrelin-evoked glucagon
secretion from the pancreas of diabetic rats. Neuro Endocrinology Letters,
23(5-6), 432–436.
Adeghate, E., & Ponery, A. S. (2002). Ghrelin stimulates insulin secretion from the
pancreas of normal and diabetic rats. Journal of Neuroendocrinology, 14(7),
555–560.
Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin
release from the pancreas of normal and diabetic rats. Neuro Endocrinology
Letters, 25(6), 403–406.
Adeghate, E., Schattner, P., & Dunn, E. (2006a). An update on the etiology and
epidemiology of diabetes mellitus. Annals of the New York Academy of
Sciences, 1084, 1–29. http://doi.org/10.1196/annals.1372.029
Adeghate, E., Schattner, P., & Dunn, E. (2006b). An update on the etiology and
epidemiology of diabetes mellitus. Annals of the New York Academy of
Sciences, 1084, 1–29. http://doi.org/10.1196/annals.1372.029
Ahmed, A. M. (2002). History of diabetes mellitus. Saudi Medical Journal, 23(4),
373–378.

91

Ahrén, B. (2003). Gut peptides and type 2 diabetes mellitus treatment. Current
Diabetes Reports, 3(5), 365–372. http://doi.org/10.1007/s11892-003-0079-9
Akamizu, T., Takaya, K., Irako, T., Hosoda, H., Teramukai, S., Matsuyama, A., …
Kangawa, K. (2004). Pharmacokinetics, safety, and endocrine and appetite
effects of ghrelin administration in young healthy subjects. European
Journal of Endocrinology, 150(4), 447–455.
http://doi.org/10.1530/eje.0.1500447
Akbarzadeh, A., Norouzian, D., Mehrabi, M. R., Jamshidi, S., Farhangi, A., Verdi,
A. A., … Rad, B. L. (2007). Induction of diabetes by Streptozotocin in rats.
Indian Journal of Clinical Biochemistry: IJCB, 22(2), 60–64.
http://doi.org/10.1007/BF02913315
Al-Disi, D., Al-Daghri, N., Khanam, L., Al-Othman, A., Al-Saif, M., Sabico, S., &
Chrousos, G. (2010). Subjective sleep duration and quality influence diet
composition and circulating adipocytokines and ghrelin levels in teen-age
girls. Endocrine Journal, 57(10), 915–923.
American Diabetes Association. (2014). Diagnosis and Classification of Diabetes
Mellitus. Diabetes Care, 37(Supplement_1), S81–S90.
http://doi.org/10.2337/dc14-S081
Andralojc, K. M., Mercalli, A., Nowak, K. W., Albarello, L., Calcagno, R., Luzi, L.,
… Piemonti, L. (2009a). Ghrelin-producing epsilon cells in the developing
and adult human pancreas. Diabetologia, 52(3), 486–493.
http://doi.org/10.1007/s00125-008-1238-y
Andralojc, K. M., Mercalli, A., Nowak, K. W., Albarello, L., Calcagno, R., Luzi, L.,
… Piemonti, L. (2009b). Ghrelin-producing epsilon cells in the developing

92

and adult human pancreas. Diabetologia, 52(3), 486–493.
http://doi.org/10.1007/s00125-008-1238-y
Aragon, G., & Younossi, Z. M. (2010). When and how to evaluate mildly elevated
liver enzymes in apparently healthy patients. Cleveland Clinic Journal of
Medicine, 77(3), 195–204. http://doi.org/10.3949/ccjm.77a.09064
Arosio, M., Ronchi, C. L., Gebbia, C., Cappiello, V., Beck-Peccoz, P., & Peracchi,
M. (2003). Stimulatory effects of ghrelin on circulating somatostatin and
pancreatic polypeptide levels. The Journal of Clinical Endocrinology and
Metabolism, 88(2), 701–704. http://doi.org/10.1210/jc.2002-021161
Asakawa, A., Inui, A., Yuzuriha, H., Ueno, N., Katsuura, G., Fujimiya, M., …
Kasuga, M. (2003). Characterization of the effects of pancreatic polypeptide
in the regulation of energy balance. Gastroenterology, 124(5), 1325–1336.
Ashrafi, M., Sheikhan, F., Arabipoor, A., Hosseini, R., Nourbakhsh, F., &
Zolfaghari, Z. (2014). Gestational diabetes mellitus risk factors in women
with polycystic ovary syndrome (PCOS). European Journal of Obstetrics,
Gynecology, and Reproductive Biology, 181C, 195–199.
http://doi.org/10.1016/j.ejogrb.2014.07.043
Avau, B., De Smet, B., Thijs, T., Geuzens, A., Tack, J., Vanden Berghe, P., &
Depoortere, I. (2013). Ghrelin is involved in the paracrine communication
between neurons and glial cells. Neurogastroenterology and Motility: The
Official Journal of the European Gastrointestinal Motility Society, 25(9),
e599–608. http://doi.org/10.1111/nmo.12171
Baker, S. (2004). Diagnosis and management of acute pancreatitis. Critical Care
and Resuscitation: Journal of the Australasian Academy of Critical Care
Medicine, 6(1), 17–27.

93

Barrett, K. E., Ghishan, F. K., Merchant, J. L., Said, H. M., & Wood, J. D. (2006).
Physiology of the Gastrointestinal Tract. Academic Press.
Beck, B., Musse, N., & Stricker-Krongrad, A. (2002). Ghrelin, macronutrient intake
and dietary preferences in long-evans rats. Biochemical and Biophysical
Research Communications, 292(4), 1031–1035.
http://doi.org/10.1006/bbrc.2002.6737
Bellar, D., Glickman, E. L., Judge, L. W., & Gunstad, J. (2013). Serum ghrelin is
associated with verbal learning and adiposity in a sample of healthy, fit older
adults. BioMed Research International, 2013, 202757.
http://doi.org/10.1155/2013/202757
Bockman, D. E., Büchler, M., & Beger, H. G. (1986). Structure and function of
specialized cilia in the exocrine pancreas. International Journal of
Pancreatology: Official Journal of the International Association of
Pancreatology, 1(1), 21–28. http://doi.org/10.1007/BF02795236
Bonora, E. (2008). Protection of pancreatic beta-cells: is it feasible? Nutrition,
Metabolism, and Cardiovascular Diseases: NMCD, 18(1), 74–83.
http://doi.org/10.1016/j.numecd.2007.05.004
Braganza, J. M., Lee, S. H., McCloy, R. F., & McMahon, M. J. (2011). Chronic
pancreatitis. The Lancet, 377(9772), 1184–1197.
http://doi.org/10.1016/S0140-6736(10)61852-1
Brissova, M., Fowler, M. J., Nicholson, W. E., Chu, A., Hirshberg, B., Harlan, D.
M., & Powers, A. C. (2005). Assessment of Human Pancreatic Islet
Architecture and Composition by Laser Scanning Confocal Microscopy.
Journal of Histochemistry & Cytochemistry, 53(9), 1087–1097.
http://doi.org/10.1369/jhc.5C6684.2005

94

Brown, M., & Vale, W. (1976). Effects of neurotensin and substance p on plasma
insulin, glucagon and glucose levels. Endocrinology, 98(3), 819–822.
http://doi.org/10.1210/endo-98-3-819
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., &
Caicedo, A. (2006). The unique cytoarchitecture of human pancreatic islets
has implications for islet cell function. Proceedings of the National Academy
of Sciences of the United States of America, 103(7), 2334–2339.
http://doi.org/10.1073/pnas.0510790103
Camiña, J. P., Carreira, M. C., Micic, D., Pombo, M., Kelestimur, F., Dieguez, C., &
Casanueva, P. F. F. (2003). Regulation of ghrelin secretion and action.
Endocrine, 22(1), 5–12. http://doi.org/10.1385/ENDO:22:1:5
Campbell, F., & Verbeke, C. S. (2013). Pathology of the Pancreas: A Practical
Approach. Springer Science & Business Media.
Carlini, V. P., Monzón, M. E., Varas, M. M., Cragnolini, A. B., Schiöth, H. B.,
Scimonelli, T. N., & de Barioglio, S. R. (2002). Ghrelin increases anxietylike behavior and memory retention in rats. Biochemical and Biophysical
Research Communications, 299(5), 739–743.
Chabot, F., Caron, A., Laplante, M., & St-Pierre, D. H. (2014). Interrelationships
between ghrelin, insulin and glucose homeostasis: Physiological relevance.
World Journal of Diabetes, 5(3), 328–341.
http://doi.org/10.4239/wjd.v5.i3.328
Chanoine, J.-P., & Wong, A. C. K. (2004). Ghrelin gene expression is markedly
higher in fetal pancreas compared with fetal stomach: effect of maternal
fasting. Endocrinology, 145(8), 3813–3820. http://doi.org/10.1210/en.20040053

95

Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., …
Horowitz, M. (2005). Effect of pramlintide on satiety and food intake in
obese subjects and subjects with type 2 diabetes. Diabetologia, 48(5), 838–
848. http://doi.org/10.1007/s00125-005-1732-4
Clark, M. A., Harvey, R. A., Finkel, R., Rey, J. A., & Whalen, K. (2011).
Pharmacology. Lippincott Williams & Wilkins.
Colberg, S., & Swain, D. (2000). Exercise and Diabetes Control A Winning
Combination. The Physician and Sportsmedicine, 28(4), 0.
http://doi.org/10.3810/psm.2000.04.843
Committee, J. F. (2014). British National Formulary (BNF) 67. Pharmaceutical
Press.
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W.,
Nyce, M. R., … Caro, J. F. (1996). Serum Immunoreactive-Leptin
Concentrations in Normal-Weight and Obese Humans. New England Journal
of Medicine, 334(5), 292–295.
http://doi.org/10.1056/NEJM199602013340503
Cummings, B. P. (2013). Leptin therapy in type 2 diabetes. Diabetes, Obesity and
Metabolism, 15(7), 607–612. http://doi.org/10.1111/dom.12048
Cummings, D. E., Frayo, R. S., Marmonier, C., Aubert, R., & Chapelot, D. (2004).
Plasma ghrelin levels and hunger scores in humans initiating meals
voluntarily without time- and food-related cues. American Journal of
Physiology - Endocrinology and Metabolism, 287(2), E297–E304.
http://doi.org/10.1152/ajpendo.00582.2003

96

Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., &
Weigle, D. S. (2001). A preprandial rise in plasma ghrelin levels suggests a
role in meal initiation in humans. Diabetes, 50(8), 1714–1719.
Damasceno, D. C., Netto, A. O., Iessi, I. L., Gallego, F. Q., Corvino, S. B.,
Dallaqua, B., … Rudge, M. V. C. (2014). Streptozotocin-Induced Diabetes
Models: Pathophysiological Mechanisms and Fetal Outcomes. BioMed
Research International, 2014, e819065. http://doi.org/10.1155/2014/819065
Datar, P., Srivastava, S., Coutinho, E., & Govil, G. (2004). Substance P: Structure,
Function, and Therapeutics. Current Topics in Medicinal Chemistry, 4(1),
75–103. http://doi.org/10.2174/1568026043451636
Date, Y. (2012). Ghrelin and the vagus nerve. Methods in Enzymology, 514, 261–
269. http://doi.org/10.1016/B978-0-12-381272-8.00016-7
Date, Y., Nakazato, M., Hashiguchi, S., Dezaki, K., Mondal, M. S., Hosoda, H., …
Matsukura, S. (2002). Ghrelin Is Present in Pancreatic α-Cells of Humans
and Rats and Stimulates Insulin Secretion. Diabetes, 51(1), 124–129.
http://doi.org/10.2337/diabetes.51.1.124
Date, Y., Nakazato, M., Murakami, N., Kojima, M., Kangawa, K., & Matsukura, S.
(2001). Ghrelin acts in the central nervous system to stimulate gastric acid
secretion. Biochemical and Biophysical Research Communications, 280(3),
904–907. http://doi.org/10.1006/bbrc.2000.4212
Davenport, A. P., Bonner, T. I., Foord, S. M., Harmar, A. J., Neubig, R. R., Pin, J.P., … Kangawa, K. (2005). International Union of Pharmacology. LVI.
Ghrelin Receptor Nomenclature, Distribution, and Function.
Pharmacological Reviews, 57(4), 541–546. http://doi.org/10.1124/pr.57.4.1

97

Delhanty, P. J. D., & van der Lely, A. J. (2013). Ghrelin: a new treatment for nonalcoholic fatty liver disease? Endocrine, 43(2), 247–248.
http://doi.org/10.1007/s12020-012-9800-2
Delporte, C. (2013). Structure and physiological actions of ghrelin. Scientifica,
2013, 518909. http://doi.org/10.1155/2013/518909
De Meyts, P. (2004). Insulin and its receptor: structure, function and evolution.
BioEssays: News and Reviews in Molecular, Cellular and Developmental
Biology, 26(12), 1351–1362. http://doi.org/10.1002/bies.20151
De Vriese, C., Grégoire, F., De Neef, P., Robberecht, P., & Delporte, C. (2005).
Ghrelin is produced by the human erythroleukemic HEL cell line and
involved in an autocrine pathway leading to cell proliferation.
Endocrinology, 146(3), 1514–1522. http://doi.org/10.1210/en.2004-0964
Dezaki, K., Damdindorj, B., Sone, H., Dyachok, O., Tengholm, A., Gylfe, E., …
Yada, T. (2011). Ghrelin attenuates cAMP-PKA signaling to evoke
insulinostatic cascade in islet β-cells. Diabetes, 60(9), 2315–2324.
http://doi.org/10.2337/db11-0368
Dezaki, K., Sone, H., Koizumi, M., Nakata, M., Kakei, M., Nagai, H., … Yada, T.
(2006). Blockade of pancreatic islet-derived ghrelin enhances insulin
secretion to prevent high-fat diet-induced glucose intolerance. Diabetes,
55(12), 3486–3493. http://doi.org/10.2337/db06-0878
Diabetes Atlas | International Diabetes Federation. (n.d.). Retrieved July 11, 2014,
from http://www.idf.org/diabetesatlas
diabetes symptoms | Pharma Mirror Magazine. (n.d.). Retrieved from
https://pharmamirror.wordpress.com/tag/diabetes-symptoms/

98

Diagnosis and Classification of Diabetes Mellitus. (2010). Diabetes Care, 33(Suppl
1), S62–S69. http://doi.org/10.2337/dc10-S062
DiMagno, M. J., & DiMagno, E. P. (2012). Chronic pancreatitis. Current Opinion in
Gastroenterology, 28(5), 523–531.
http://doi.org/10.1097/MOG.0b013e3283567dea
DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M.
(2011). Pharmacotherapy: A Pathophysiologic Approach, Eighth Edition.
McGraw Hill Professional.
dLife Diabetes Museum. (n.d.). Retrieved July 4, 2014, from
http://www.dlife.com/files/Timeline/
Doogue, M. P., Begg, E. J., Moore, M. P., Lunt, H., Pemberton, C. J., & Zhang, M.
(2009). Metformin increases plasma ghrelin in Type 2 diabetes. British
Journal of Clinical Pharmacology, 68(6), 875–882.
http://doi.org/10.1111/j.1365-2125.2009.03372.x
Drucker, D. J. (1998). Glucagon-Like Peptides. Diabetes, 47(2), 159–169.
http://doi.org/10.2337/diab.47.2.159
Drucker, D. J., & Nauck, M. A. (2006). The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
The Lancet, 368(9548), 1696–1705. http://doi.org/10.1016/S01406736(06)69705-5
Du, C.-K., Zhan, D.-Y., Morimoto, S., Akiyama, T., Schwenke, D. O., Hosoda, H.,
… Shirai, M. (2014). Survival benefit of ghrelin in the heart failure due to
dilated cardiomyopathy. Pharmacology Research & Perspectives, 2(5),
e00064. http://doi.org/10.1002/prp2.64

99

Efrat, S., & Russ, H. A. (2012). Making β cells from adult tissues. Trends in
Endocrinology & Metabolism, 23(6), 278–285.
http://doi.org/10.1016/j.tem.2012.03.005
English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C. G., Harrison,
J., … Wilding, J. P. H. (2007). Metformin prolongs the postprandial fall in
plasma ghrelin concentrations in type 2 diabetes. Diabetes/Metabolism
Research and Reviews, 23(4), 299–303. http://doi.org/10.1002/dmrr.681
English, P. J., Ghatei, M. A., Malik, I. A., Bloom, S. R., & Wilding, J. P. H. (2002).
Food fails to suppress ghrelin levels in obese humans. The Journal of
Clinical Endocrinology and Metabolism, 87(6), 2984.
http://doi.org/10.1210/jcem.87.6.8738
Eroschenko, V. P. (2008). DiFiore’s Atlas of Histology with Functional
Correlations. Lippincott Williams & Wilkins.
Estep, M., Abawi, M., Jarrar, M., Wang, L., Stepanova, M., Elariny, H., …
Younossi, Z. M. (2011). Association of obestatin, ghrelin, and inflammatory
cytokines in obese patients with non-alcoholic fatty liver disease. Obesity
Surgery, 21(11), 1750–1757. http://doi.org/10.1007/s11695-011-0475-1
Faiz, O., & Moffat, D. (2006). Anatomy at a Glance. Wiley.
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., …
Perfetti, R. (2003). Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and
Improves Glucose Responsiveness of Freshly Isolated Human Islets.
Endocrinology, 144(12), 5149–5158. http://doi.org/10.1210/en.2003-0323
Farney, A. C., Cho, E., Schweitzer, E. J., Dunkin, B., Philosophe, B., Colonna, J., …
Bartlett, S. T. (2000). Simultaneous Cadaver Pancreas Living-Donor Kidney

100

Transplantation: A New Approach for the Type 1 Diabetic Uremic Patient.
Annals of Surgery, 232(5), 696–703.
Figueiro, M. G., Plitnick, B., & Rea, M. S. (2012). Light modulates leptin and
ghrelin in sleep-restricted adults. International Journal of Endocrinology,
2012, 530726. http://doi.org/10.1155/2012/530726
Fiorina, P., Folli, F., Zerbini, G., Maffi, P., Gremizzi, C., Carlo, V. D., … Secchi, A.
(2003). Islet Transplantation Is Associated with Improvement of Renal
Function among Uremic Patients with Type I Diabetes Mellitus and Kidney
Transplants. Journal of the American Society of Nephrology, 14(8), 2150–
2158. http://doi.org/10.1097/01.ASN.0000077339.20759.A3
Frossard, J.-L., Steer, M. L., & Pastor, C. M. (2008). Acute pancreatitis. Lancet,
371(9607), 143–152. http://doi.org/10.1016/S0140-6736(08)60107-5
Gahete, M. D., Córdoba-Chacón, J., Hergueta-Redondo, M., Martínez-Fuentes, A.
J., Kineman, R. D., Moreno-Bueno, G., … Castaño, J. P. (2011). A Novel
Human Ghrelin Variant (In1-Ghrelin) and Ghrelin-O-Acyltransferase Are
Overexpressed in Breast Cancer: Potential Pathophysiological Relevance.
PLoS ONE, 6(8), e23302. http://doi.org/10.1371/journal.pone.0023302
Gahete, M. D., Rincón-Fernández, D., Villa-Osaba, A., Hormaechea-Agulla, D.,
Ibáñez-Costa, A., Martínez-Fuentes, A. J., … Luque, R. M. (2014). Ghrelin
gene products, receptors, and GOAT enzyme: biological and
pathophysiological insight. The Journal of Endocrinology, 220(1), R1–24.
http://doi.org/10.1530/JOE-13-0391
Ganong, W. (2005). Review of Medical Physiology. McGraw Hill Professional.
García-García, F., Juárez-Aguilar, E., Santiago-García, J., & Cardinali, D. P. (2014).
Ghrelin and its interactions with growth hormone, leptin and orexins:

101

implications for the sleep-wake cycle and metabolism. Sleep Medicine
Reviews, 18(1), 89–97. http://doi.org/10.1016/j.smrv.2013.04.003
Gastón, M. S., Schiöth, H. B., De Barioglio, S. R., & Salvatierra, N. A. (2015).
Gabaergic control of anxiety-like behavior, but not food intake, induced by
ghrelin in the intermediate medial mesopallium of the neonatal chick.
Hormones and Behavior, 67, 66–72.
http://doi.org/10.1016/j.yhbeh.2014.11.015
Gelling, R. W., Overduin, J., Morrison, C. D., Morton, G. J., Frayo, R. S.,
Cummings, D. E., & Schwartz, M. W. (2004). Effect of uncontrolled
diabetes on plasma ghrelin concentrations and ghrelin-induced feeding.
Endocrinology, 145(10), 4575–4582. http://doi.org/10.1210/en.2004-0605
Gillespie, K. M. (2006). Type 1 diabetes: pathogenesis and prevention. CMAJ:
Canadian Medical Association Journal = Journal de l’Association Medicale
Canadienne, 175(2), 165–170. http://doi.org/10.1503/cmaj.060244
Gnanapavan, S., Kola, B., Bustin, S. A., Morris, D. G., McGee, P., Fairclough, P.,
… Korbonits, M. (2002). The Tissue Distribution of the mRNA of Ghrelin
and Subtypes of Its Receptor, GHS-R, in Humans. The Journal of Clinical
Endocrinology & Metabolism, 87(6), 2988–2988.
http://doi.org/10.1210/jcem.87.6.8739
Goshadrou, F., Kermani, M., Ronaghi, A., & Sajjadi, S. (2013). The effect of ghrelin
on MK-801 induced memory impairment in rats. Peptides, 44, 60–65.
http://doi.org/10.1016/j.peptides.2013.03.022
Goto, M., Arima, H., Watanabe, M., Hayashi, M., Banno, R., Sato, I., … Oiso, Y.
(2006). Ghrelin increases neuropeptide Y and agouti-related peptide gene

102

expression in the arcuate nucleus in rat hypothalamic organotypic cultures.
Endocrinology, 147(11), 5102–5109. http://doi.org/10.1210/en.2006-0104
Greenstein, B., & Wood, D. (2011). The Endocrine System at a Glance. Wiley.
Gruessner, A. C., & Sutherland, D. E. R. (2005). Pancreas transplant outcomes for
United States (US) and non-US cases as reported to the United Network for
Organ Sharing (UNOS) and the International Pancreas Transplant Registry
(IPTR) as of June 2004. Clinical Transplantation, 19(4), 433–455.
http://doi.org/10.1111/j.1399-0012.2005.00378.x
Gualillo, O., Caminos, J., Blanco, M., Garcìa-Caballero, T., Kojima, M., Kangawa,
K., … Casanueva, F. (2001). Ghrelin, a novel placental-derived hormone.
Endocrinology, 142(2), 788–794. http://doi.org/10.1210/endo.142.2.7987
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., &
Shaw, J. E. (2014). Global estimates of diabetes prevalence for 2013 and
projections for 2035. Diabetes Research and Clinical Practice, 103(2), 137–
149. http://doi.org/10.1016/j.diabres.2013.11.002
Hansen, T. K., Dall, R., Hosoda, H., Kojima, M., Kangawa, K., Christiansen, J. S.,
& Jørgensen, J. O. L. (2002). Weight loss increases circulating levels of
ghrelin in human obesity. Clinical Endocrinology, 56(2), 203–206.
http://doi.org/10.1046/j.0300-0664.2001.01456.x
Harrison, S., & Geppetti, P. (2001). Substance P. The International Journal of
Biochemistry & Cell Biology, 33(6), 555–576. http://doi.org/10.1016/S13572725(01)00031-0
Harvey, R. A., & Ferrier, D. R. (2011). Biochemistry. Lippincott Williams &
Wilkins.

103

Hattori, N., Saito, T., Yagyu, T., Jiang, B.-H., Kitagawa, K., & Inagaki, C. (2001).
GH, GH Receptor, GH Secretagogue Receptor, and Ghrelin Expression in
Human T Cells, B Cells, and Neutrophils. The Journal of Clinical
Endocrinology & Metabolism, 86(9), 4284–4291.
http://doi.org/10.1210/jcem.86.9.7866
Heinemann, L. (2010). New ways of insulin delivery. International Journal of
Clinical Practice. Supplement, (166), 29–40. http://doi.org/10.1111/j.17421241.2009.02276.x
Heppner, K. M., Müller, T. D., Tong, J., & Tschöp, M. H. (2012). Ghrelin in the
control of energy, lipid, and glucose metabolism. Methods in Enzymology,
514, 249–260. http://doi.org/10.1016/B978-0-12-381272-8.00015-5
Hermansen, K. (1980). Effects of Substance P and Other Peptides on the Release of
Somatostatin, Insulin, and Glucagon in Vitro. Endocrinology, 107(1), 256–
261. http://doi.org/10.1210/endo-107-1-256
Hickey, M. S., Considine, R. V., Israel, R. G., Mahar, T. L., McCammon, M. R.,
Tyndall, G. L., … Caro, J. F. (1996). Leptin is related to body fat content in
male distance runners. The American Journal of Physiology, 271(5 Pt 1),
E938–940.
Higgins, S. C., Gueorguiev, M., & Korbonits, M. (2007). Ghrelin, the peripheral
hunger hormone. Annals of Medicine, 39(2), 116–136.
http://doi.org/10.1080/07853890601149179
Horton, E. S. (1988). Role and Management of Exercise in Diabetes Mellitus.
Diabetes Care, 11(2), 201–211. http://doi.org/10.2337/diacare.11.2.201
Hosoda, H., Kojima, M., Matsuo, H., & Kangawa, K. (2000). Ghrelin and des-acyl
ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue.

104

Biochemical and Biophysical Research Communications, 279(3), 909–913.
http://doi.org/10.1006/bbrc.2000.4039
Hosoda, H., Kojima, M., Mizushima, T., Shimizu, S., & Kangawa, K. (2003).
Structural divergence of human ghrelin. Identification of multiple ghrelinderived molecules produced by post-translational processing. The Journal of
Biological Chemistry, 278(1), 64–70.
http://doi.org/10.1074/jbc.M205366200
Hotta, M., Ohwada, R., Akamizu, T., Shibasaki, T., Takano, K., & Kangawa, K.
(2009). Ghrelin Increases Hunger and Food Intake in Patients with
Restricting-type Anorexia Nervosa: A Pilot Study. Endocrine Journal, 56(9),
1119–1128. http://doi.org/10.1507/endocrj.K09E-168
Howard, A. D., McAllister, G., Feighner, S. D., Liu, Q., Nargund, R. P., Van der
Ploeg, L. H. T., & Patchett, A. A. (2001). Orphan G-protein-coupled
receptors and natural ligand discovery. Trends in Pharmacological Sciences,
22(3), 132–140. http://doi.org/10.1016/S0165-6147(00)01636-9
Howarth, F. C. (2013). Epidemiology of Diabetes Mellitus – A Global and Regional
Perspective. HAMDAN MEDICAL JOURNAL, 6(1).
http://doi.org/10.7707/hmj.v6i1.149
Hubbard, S. R. (2013). Structural biology: Insulin meets its receptor. Nature,
493(7431), 171–172. http://doi.org/10.1038/493171a
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., &
Willett, W. C. (2001). Diet, Lifestyle, and the Risk of Type 2 Diabetes
Mellitus in Women. New England Journal of Medicine, 345(11), 790–797.
http://doi.org/10.1056/NEJMoa010492

105

Jeffery, P. L., Herington, A. C., & Chopin, L. K. (2003). The potential
autocrine/paracrine roles of ghrelin and its receptor in hormone-dependent
cancer. Cytokine & Growth Factor Reviews, 14(2), 113–122.
Kadoglou, N. P. E., Vrabas, I. S., Kapelouzou, A., Lampropoulos, S., Sailer, N.,
Kostakis, A., … Angelopoulou, N. (2012). The impact of aerobic exercise
training on novel adipokines, apelin and ghrelin, in patients with type 2
diabetes. Medical Science Monitor: International Medical Journal of
Experimental and Clinical Research, 18(5), CR290–295.
Kageyama, H., Funahashi, H., Hirayama, M., Takenoya, F., Kita, T., Kato, S., …
Shioda, S. (2005a). Morphological analysis of ghrelin and its receptor
distribution in the rat pancreas. Regulatory Peptides, 126(1-2), 67–71.
http://doi.org/10.1016/j.regpep.2004.08.031
Kageyama, H., Funahashi, H., Hirayama, M., Takenoya, F., Kita, T., Kato, S., …
Shioda, S. (2005b). Morphological analysis of ghrelin and its receptor
distribution in the rat pancreas. Regulatory Peptides, 126(1-2), 67–71.
http://doi.org/10.1016/j.regpep.2004.08.031
Kageyama, H., Funahashi, H., Hirayama, M., Takenoya, F., Kita, T., Kato, S., …
Shioda, S. (2005c). Morphological analysis of ghrelin and its receptor
distribution in the rat pancreas. Regulatory Peptides, 126(1-2), 67–71.
http://doi.org/10.1016/j.regpep.2004.08.031
Kahn, C. R., & White, M. F. (1988). The insulin receptor and the molecular
mechanism of insulin action. The Journal of Clinical Investigation, 82(4),
1151–1156. http://doi.org/10.1172/JCI113711

106

Kahn, S. E. (2000). The importance of the β-cell in the pathogenesis of type 2
diabetes mellitus1. The American Journal of Medicine, 108(6, Supplement
1), 2–8. http://doi.org/10.1016/S0002-9343(00)00336-3
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006). Mechanisms linking obesity
to insulin resistance and type 2 diabetes. Nature, 444(7121), 840–846.
http://doi.org/10.1038/nature05482
Kalra, S. P. (2013). Should leptin replace insulin as a lifetime monotherapy for
diabetes type 1 and 2? Indian Journal of Endocrinology and Metabolism,
17(Suppl1), S23–S24. http://doi.org/10.4103/2230-8210.119496
Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., & Wakabayashi, I.
(2000). Central effect of ghrelin, an endogenous growth hormone
secretagogue, on hypothalamic peptide gene expression. Endocrinology,
141(12), 4797–4800. http://doi.org/10.1210/endo.141.12.7920
Kamegai, J., Tamura, H., Shimizu, T., Ishii, S., Sugihara, H., & Wakabayashi, I.
(2001). Chronic central infusion of ghrelin increases hypothalamic
neuropeptide Y and Agouti-related protein mRNA levels and body weight in
rats. Diabetes, 50(11), 2438–2443.
Karamitsos, D. T. (2011). The story of insulin discovery. Diabetes Research and
Clinical Practice, 93, Supplement 1, S2–S8. http://doi.org/10.1016/S01688227(11)70007-9
Katsuki, A., Urakawa, H., Gabazza, E. C., Murashima, S., Nakatani, K., Togashi,
K., … Sumida, Y. (2004). Circulating levels of active ghrelin is associated
with abdominal adiposity, hyperinsulinemia and insulin resistance in patients
with type 2 diabetes mellitus. European Journal of Endocrinology, 151(5),
573–577. http://doi.org/10.1530/eje.0.1510573

107

Katzung, B. G. (2007). Basic & Clinical Pharmacology. McGraw-Hill Medical.
Kelly, W. D., Lillehei, R. C., Merkel, F. K., Idezuki, Y., & Goetz, F. C. (1967).
Allotransplantation of the pancreas and duodenum along with the kidney in
diabetic nephropathy. Surgery, 61(6), 827–837.
Kendall, D. M. (2006). Thiazolidinediones The case for early use. Diabetes Care,
29(1), 154–157. http://doi.org/10.2337/diacare.29.01.06.dc05-0711
Kido, Y., Nakae, J., & Accili, D. (2001). Clinical review 125: The insulin receptor
and its cellular targets. The Journal of Clinical Endocrinology and
Metabolism, 86(3), 972–979. http://doi.org/10.1210/jcem.86.3.7306
Kleinwechter, H., Schäfer-Graf, U., Bührer, C., Hoesli, I., Kainer, F., KautzkyWiller, A., … Sorger, M. (2014). Gestational diabetes mellitus (GDM)
diagnosis, therapy and follow-up care: Practice Guideline of the German
Diabetes Association(DDG) and the German Association for
Gynaecologyand Obstetrics (DGGG). Experimental and Clinical
Endocrinology & Diabetes: Official Journal, German Society of
Endocrinology [and] German Diabetes Association, 122(7), 395–405.
http://doi.org/10.1055/s-0034-1366412
Kohno, D., Sone, H., Minokoshi, Y., & Yada, T. (2008). Ghrelin raises [Ca2+]i via
AMPK in hypothalamic arcuate nucleus NPY neurons. Biochemical and
Biophysical Research Communications, 366(2), 388–392.
http://doi.org/10.1016/j.bbrc.2007.11.166
Kojima, M. (2008). The discovery of ghrelin--a personal memory. Regulatory
Peptides, 145(1-3), 2–6. http://doi.org/10.1016/j.regpep.2007.09.023

108

Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K.
(1999). Ghrelin is a growth-hormone-releasing acylated peptide from
stomach. Nature, 402(6762), 656–660. http://doi.org/10.1038/45230
Kojima, M., Hosoda, H., & Kangawa, K. (2012). Purification of rat and human
ghrelins. Methods in Enzymology, 514, 45–61. http://doi.org/10.1016/B9780-12-381272-8.00003-9
Kojima, M., & Kangawa, K. (2005). Ghrelin: Structure and Function. Physiological
Reviews, 85(2), 495–522. http://doi.org/10.1152/physrev.00012.2004
Kojima, M., & Kangawa, K. (2011). The discovery of ghrelin: with a little luck and
great passion. Preface. Peptides, 32(11), 2153–2154.
http://doi.org/10.1016/j.peptides.2011.10.016
Kunt, T., Forst, T., Schmidt, S., Pfützner, A., Schneider, S., Harzer, O., … Beyer, J.
(2000). Serum levels of substance P are decreased in patients with type 1
diabetes. Experimental and Clinical Endocrinology &amp; Diabetes, 108(3),
164–167. http://doi.org/10.1055/s-2000-7738
Lanfranco, F., Baldi, M., Cassoni, P., Bosco, M., Ghé, C., & Muccioli, G. (2008).
Ghrelin and prostate cancer. Vitamins and Hormones, 77, 301–324.
http://doi.org/10.1016/S0083-6729(06)77013-3
Lawrence, C. B., Snape, A. C., Baudoin, F. M.-H., & Luckman, S. M. (2002). Acute
central ghrelin and GH secretagogues induce feeding and activate brain
appetite centers. Endocrinology, 143(1), 155–162.
http://doi.org/10.1210/endo.143.1.8561
Leahy, J. L. (2005). Pathogenesis of Type 2 Diabetes Mellitus. Archives of Medical
Research, 36(3), 197–209. http://doi.org/10.1016/j.arcmed.2005.01.003

109

Lee, H.-M., Wang, G., Englander, E. W., Kojima, M., & Greeley, G. H. (2002).
Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin
secretion: enteric distribution, ontogeny, influence of endocrine, and dietary
manipulations. Endocrinology, 143(1), 185–190.
http://doi.org/10.1210/endo.143.1.8602
Legakis, I., Stathopoulos, J., Matzouridis, T., & Stathopoulos, G. P. (2009).
Decreased plasma ghrelin levels in patients with advanced cancer and weight
loss in comparison to healthy individuals. Anticancer Research, 29(10),
3949–3952.
Lenzen, S. (2008). The mechanisms of alloxan- and streptozotocin-induced diabetes.
Diabetologia, 51(2), 216–226. http://doi.org/10.1007/s00125-007-0886-7
Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004). Pancreatic cancer. The
Lancet, 363(9414), 1049–1057. http://doi.org/10.1016/S01406736(04)15841-8
Li, E., Chung, H., Kim, Y., Kim, D. H., Ryu, J. H., Sato, T., … Park, S. (2013).
Ghrelin directly stimulates adult hippocampal neurogenesis: implications for
learning and memory. Endocrine Journal, 60(6), 781–789.
Lin, S., Chen, Z., Lin, C., & Duan, H. (2009). [Effects of glucagon on plasma
ghrelin level in type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi, 89(14),
967–969.
Lotfy, M., Singh, J., Kalász, H., Tekes, K., & Adeghate, E. (2011). Medicinal
Chemistry and Applications of Incretins and DPP-4 Inhibitors in the
Treatment of Type 2 Diabetes Mellitus. The Open Medicinal Chemistry
Journal, 5(Suppl 2), 82–92. http://doi.org/10.2174/1874104501105010082

110

Lundquist, I., Sundler, F., Ahrén, B., Alumets, J., & Håkanson, R. (1979).
Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular
distribution and effects on stimulated insulin secretion in the mouse.
Endocrinology, 104(3), 832–838. http://doi.org/10.1210/endo-104-3-832
Malagón, M. M., Luque, R. M., Ruiz-Guerrero, E., Rodríguez-Pacheco, F., GarcíaNavarro, S., Casanueva, F. F., … Castaño, J. P. (2003). Intracellular
signaling mechanisms mediating ghrelin-stimulated growth hormone release
in somatotropes. Endocrinology, 144(12), 5372–5380.
http://doi.org/10.1210/en.2003-0723
Martin, K. A., Merenick, B. L., Ding, M., Fetalvero, K. M., Rzucidlo, E. M., Kozul,
C. D., … Powell, R. J. (2007). Rapamycin promotes vascular smooth muscle
cell differentiation through insulin receptor substrate-1/phosphatidylinositol
3-kinase/Akt2 feedback signaling. The Journal of Biological Chemistry,
282(49), 36112–36120. http://doi.org/10.1074/jbc.M703914200
Masuda, Y., Tanaka, T., Inomata, N., Ohnuma, N., Tanaka, S., Itoh, Z., …
Kangawa, K. (2000). Ghrelin Stimulates Gastric Acid Secretion and Motility
in Rats. Biochemical and Biophysical Research Communications, 276(3),
905–908. http://doi.org/10.1006/bbrc.2000.3568
McCall, M., & Shapiro, A. M. J. (2014). Islet cell transplantation. Seminars in
Pediatric Surgery, 23(2), 83–90.
http://doi.org/10.1053/j.sempedsurg.2014.03.006
McLaughlin, T., Abbasi, F., Lamendola, C., Frayo, R. S., & Cummings, D. E.
(2004). Plasma ghrelin concentrations are decreased in insulin-resistant
obese adults relative to equally obese insulin-sensitive controls. The Journal

111

of Clinical Endocrinology and Metabolism, 89(4), 1630–1635.
http://doi.org/10.1210/jc.2003-031572
Miller, D. W., Harrison, J. L., Brown, Y. A., Doyle, U., Lindsay, A., Adam, C. L., &
Lea, R. G. (2005). Immunohistochemical evidence for an
endocrine/paracrine role for ghrelin in the reproductive tissues of sheep.
Reproductive Biology and Endocrinology: RB&E, 3, 60.
http://doi.org/10.1186/1477-7827-3-60
Mitchell, R. M. S., Byrne, M. F., & Baillie, J. (2003). Pancreatitis. Lancet,
361(9367), 1447–1455.
Mokdad AH, Ford ES, Bowman BA, & et al. (2003). PRevalence of obesity,
diabetes, and obesity-related health risk factors, 2001. JAMA, 289(1), 76–79.
http://doi.org/10.1001/jama.289.1.76
Moore, K. L., & Dalley, A. F. (1999). Clinically Oriented Anatomy. Lippincott
Williams & Wilkins.
Mori, K., Yoshimoto, A., Takaya, K., Hosoda, K., Ariyasu, H., Yahata, K., …
Nakao, K. (2000). Kidney produces a novel acylated peptide, ghrelin. FEBS
Letters, 486(3), 213–216. http://doi.org/10.1016/S0014-5793(00)02308-5
Mykhalchyshyn, G., Kobyliak, N., & Bodnar, P. (2015). Diagnostic accuracy of
acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2
diabetic patients. Journal of Diabetes and Metabolic Disorders, 14, 44.
http://doi.org/10.1186/s40200-015-0170-1
Nagaya, N., & Kangawa, K. (2004). [Ghrelin in the treatment of cardiovascular
disease]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 62 Suppl 9,
430–434.

112

Nakazato, M., Hashimoto, K., Shiina, A., Koizumi, H., Mitsumoti, M., Imai, M., …
Iyo, M. (2004). No changes in serum ghrelin levels in female patients with
bulimia nervosa. Progress in Neuro-Psychopharmacology & Biological
Psychiatry, 28(7), 1181–1184. http://doi.org/10.1016/j.pnpbp.2004.06.012
Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., &
Matsukura, S. (2001). A role for ghrelin in the central regulation of feeding.
Nature, 409(6817), 194–198. http://doi.org/10.1038/35051587
Nkosi, C. Z., Opoku, A. R., & Terblanche, S. E. (2006). In Vitro antioxidative
activity of pumpkin seed (Cucurbita pepo) protein isolate and its In Vivo
effect on alanine transaminase and aspartate transaminase in acetaminopheninduced liver injury in low protein fed rats. Phytotherapy Research: PTR,
20(9), 780–783. http://doi.org/10.1002/ptr.1958
Nørrelund, H., Hansen, T. K., Ørskov, H., Hosoda, H., Kojima, M., Kangawa, K., …
Jørgensen, J. O. L. (2002). Ghrelin immunoreactivity in human plasma is
suppressed by somatostatin. Clinical Endocrinology, 57(4), 539–546.
Okamatsu, Y., Matsuda, K., Hiramoto, I., Tani, H., Kimura, K., Yada, Y., …
Matsuishi, T. (2009). Ghrelin and leptin modulate immunity and liver
function in overweight children. Pediatrics International, 51(1), 9–13.
http://doi.org/10.1111/j.1442-200X.2008.02647.x
Omoto, I., Matsumoto, M., Uchikado, Y., Kita, Y., Sakurai, T., Sasaki, K., …
Natsugoe, S. (2014). Immunohistochemical evidence of association between
ghrelin expression and tumor growth in esophageal carcinoma. Anticancer
Research, 34(6), 2727–2733.
Østergård, T., Hansen, T., Nyholm, B., Gravholt, C., Djurhuus, C., Hosoda, H., …
Schmitz, O. (2003). Circulating ghrelin concentrations are reduced in healthy

113

offspring of Type 2 diabetic subjects, and are increased in women
independent of a family history of Type 2 diabetes. Diabetologia, 46(1),
134–136. http://doi.org/10.1007/s00125-002-0985-4
Osterstock, G., Escobar, P., Mitutsova, V., Gouty-Colomer, L.-A., Fontanaud, P.,
Molino, F., … Méry, P.-F. (2010). Ghrelin stimulation of growth hormonereleasing hormone neurons is direct in the arcuate nucleus. PloS One, 5(2),
e9159. http://doi.org/10.1371/journal.pone.0009159
Ozsoy, S., Besirli, A., Abdulrezzak, U., & Basturk, M. (2014). Serum ghrelin and
leptin levels in patients with depression and the effects of treatment.
Psychiatry Investigation, 11(2), 167–172.
http://doi.org/10.4306/pi.2014.11.2.167
Padoin, A. V., Galvão Neto, M., Moretto, M., Barancelli, F., Schroer, C. E., &
Mottin, C. C. (2009). Obese patients with type 2 diabetes submitted to
banded gastric bypass: greater incidence of dumping syndrome. Obesity
Surgery, 19(11), 1481–1484. http://doi.org/10.1007/s11695-009-9943-2
Pandol, S. J. (2011). The Exocrine Pancreas. Morgan & Claypool Publishers.
Papotti, M., Ghè, C., Cassoni, P., Catapano, F., Deghenghi, R., Ghigo, E., &
Muccioli, G. (2000). Growth hormone secretagogue binding sites in
peripheral human tissues. The Journal of Clinical Endocrinology and
Metabolism, 85(10), 3803–3807. http://doi.org/10.1210/jcem.85.10.6846
Pavel, I., & Sdrobici, D. (1972). [N. Paulescu, discoverer of insulin. 50th
anniversary of the discovery of that hormone]. Medicină Internă, 24(11),
1285–1294.
Perfetti, R., Zhou, J., Doyle, M. E., & Egan, J. M. (2000). Glucagon-Like Peptide-1
Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1

114

Expression and Increases Endocrine Cell Mass in the Pancreas of Old,
Glucose-Intolerant Rats. Endocrinology, 141(12), 4600–4605.
http://doi.org/10.1210/endo.141.12.7806
Petersen, O. H. (1992). Stimulus-secretion coupling: cytoplasmic calcium signals
and the control of ion channels in exocrine acinar cells. The Journal of
Physiology, 448, 1–51.
Pilcher, H. (2006). Alzheimer’s disease could be “type 3 diabetes.” The Lancet
Neurology, 5(5), 388–389. http://doi.org/10.1016/S1474-4422(06)70434-3
Piñero-Piloña, A., & Raskin, P. (2001). Idiopathic Type 1 diabetes. Journal of
Diabetes and Its Complications, 15(6), 328–335.
http://doi.org/10.1016/S1056-8727(01)00172-6
Poretti, M. B., Rask-Andersen, M., Kumar, P., Rubiales de Barioglio, S., Fiol de
Cuneo, M., Schiöth, H. B., & Carlini, V. P. (2015). Ghrelin effects
expression of several genes associated with depression-like behavior.
Progress in Neuro-Psychopharmacology & Biological Psychiatry, 56, 227–
234. http://doi.org/10.1016/j.pnpbp.2014.09.012
Pöykkö, S. M., Kellokoski, E., Hörkkö, S., Kauma, H., Kesäniemi, Y. A., & Ukkola,
O. (2003). Low Plasma Ghrelin Is Associated With Insulin Resistance,
Hypertension, and the Prevalence of Type 2. Diabetes, 52(10), 2546–2553.
http://doi.org/10.2337/diabetes.52.10.2546
Purnell, J. Q., Weigle, D. S., Breen, P., & Cummings, D. E. (2003). Ghrelin levels
correlate with insulin levels, insulin resistance, and high-density lipoprotein
cholesterol, but not with gender, menopausal status, or cortisol levels in
humans. The Journal of Clinical Endocrinology and Metabolism, 88(12),
5747–5752. http://doi.org/10.1210/jc.2003-030513

115

Qader, S. S., Lundquist, I., Ekelund, M., Håkanson, R., & Salehi, A. (2005). Ghrelin
activates neuronal constitutive nitric oxide synthase in pancreatic islet cells
while inhibiting insulin release and stimulating glucagon release. Regulatory
Peptides, 128(1), 51–56. http://doi.org/10.1016/j.regpep.2004.12.018
REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE
INTERVENTION OR METFORMIN. (2002). The New England Journal of
Medicine, 346(6), 393–403. http://doi.org/10.1056/NEJMoa012512
Reichenbach, A., Steyn, F. J., Sleeman, M. W., & Andrews, Z. B. (2012). Ghrelin
receptor expression and colocalization with anterior pituitary hormones using
a GHSR-GFP mouse line. Endocrinology, 153(11), 5452–5466.
http://doi.org/10.1210/en.2012-1622
Rena, G., Pearson, E. R., & Sakamoto, K. (2013). Molecular mechanism of action of
metformin: old or new insights? Diabetologia, 56(9), 1898–1906.
http://doi.org/10.1007/s00125-013-2991-0
Reyes-Muñoz, E., Castellanos-Barroso, G., Ramírez-Eugenio, B. Y., OrtegaGonzález, C., Parra, A., Castillo-Mora, A., & De la Jara-Díaz, J. F. (2012).
The risk of gestational diabetes mellitus among Mexican women with a
history of infertility and polycystic ovary syndrome. Fertility and Sterility,
97(6), 1467–1471. http://doi.org/10.1016/j.fertnstert.2012.03.023
Riddell, M. C., & Perkins, B. A. (2006). Type 1 Diabetes and Vigorous Exercise:
Applications of Exercise Physiology to Patient Management. Canadian
Journal of Diabetes, 30(1), 63–71. http://doi.org/10.1016/S14992671(06)01010-0

116

Riley, L. G. (2013). Different forms of ghrelin exhibit distinct biological roles in
tilapia. Frontiers in Endocrinology, 4, 118.
http://doi.org/10.3389/fendo.2013.00118
Riley, L. G., Hirano, T., & Grau, E. G. (2002). Rat ghrelin stimulates growth
hormone and prolactin release in the tilapia, Oreochromis mossambicus.
Zoological Science, 19(7), 797–800.
Robertson, R. P. (2004). Islet Transplantation as a Treatment for Diabetes — A
Work in Progress. New England Journal of Medicine, 350(7), 694–705.
http://doi.org/10.1056/NEJMra032425
Rosenfeld, L. (2002a). Insulin: Discovery and Controversy. Clinical Chemistry,
48(12), 2270–2288.
Rosenfeld, L. (2002b). Insulin: Discovery and Controversy. Clinical Chemistry,
48(12), 2270–2288.
Ross, M. H., & Pawlina, W. (2006). Histology. Lippincott Williams & Wilkins.
Saadi, H., Carruthers, S. G., Nagelkerke, N., Al-Maskari, F., Afandi, B., Reed, R.,
… Benedict, S. (2007). Prevalence of diabetes mellitus and its complications
in a population-based sample in Al Ain, United Arab Emirates. Diabetes
Research and Clinical Practice, 78(3), 369–377.
http://doi.org/10.1016/j.diabres.2007.04.008
Saito, E.-S., Kaiya, H., Tachibana, T., Tomonaga, S., Denbow, D. M., Kangawa, K.,
& Furuse, M. (2005). Inhibitory effect of ghrelin on food intake is mediated
by the corticotropin-releasing factor system in neonatal chicks. Regulatory
Peptides, 125(1–3), 201–208. http://doi.org/10.1016/j.regpep.2004.09.003
Salehi, A., Dornonville de la Cour, C., Håkanson, R., & Lundquist, I. (2004). Effects
of ghrelin on insulin and glucagon secretion: a study of isolated pancreatic

117

islets and intact mice. Regulatory Peptides, 118(3), 143–150.
http://doi.org/10.1016/j.regpep.2003.12.001
Salfen, B. E., Carroll, J. A., Keisler, D. H., & Strauch, T. A. (2004). Effects of
exogenous ghrelin on feed intake, weight gain, behavior, and endocrine
responses in weanling pigs. Journal of Animal Science, 82(7), 1957–1966.
Sato, T., Nakamura, Y., Shiimura, Y., Ohgusu, H., Kangawa, K., & Kojima, M.
(2012). Structure, regulation and function of ghrelin. Journal of
Biochemistry, 151(2), 119–128. http://doi.org/10.1093/jb/mvr134
Scherbaum, W. A. (1992). Etiology and pathogenesis of type 1 diabetes. Hormone
and Metabolic Research. Supplement Series, 26, 111–116.
Schulingkamp, R. J., Pagano, T. C., Hung, D., & Raffa, R. B. (2000). Insulin
receptors and insulin action in the brain: review and clinical implications.
Neuroscience and Biobehavioral Reviews, 24(8), 855–872.
secondary diabetes mellitus. (n.d.). Retrieved February 23, 2015, from
http://medical-dictionary.thefreedictionary.com/secondary+diabetes+mellitus
Senior, J. R. (2012). Alanine aminotransferase: a clinical and regulatory tool for
detecting liver injury-past, present, and future. Clinical Pharmacology and
Therapeutics, 92(3), 332–339. http://doi.org/10.1038/clpt.2012.108
Seoane, L. M., López, M., Tovar, S., Casanueva, F. F., Señarís, R., & Diéguez, C.
(2003). Agouti-related peptide, neuropeptide Y, and somatostatin-producing
neurons are targets for ghrelin actions in the rat hypothalamus.
Endocrinology, 144(2), 544–551. http://doi.org/10.1210/en.2002-220795
Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M. S., Tanaka, M., …
Matsukura, S. (2002). Plasma ghrelin levels in lean and obese humans and
the effect of glucose on ghrelin secretion. The Journal of Clinical

118

Endocrinology and Metabolism, 87(1), 240–244.
http://doi.org/10.1210/jcem.87.1.8129
Shimada, M., Date, Y., Mondal, M. S., Toshinai, K., Shimbara, T., Fukunaga, K., …
Nakazato, M. (2003). Somatostatin suppresses ghrelin secretion from the rat
stomach. Biochemical and Biophysical Research Communications, 302(3),
520–525.
Shousha, S., Nakahara, K., Kojima, M., Miyazato, M., Hosoda, H., Kangawa, K., &
Murakami, N. (2005). Different effects of peripheral and central ghrelin on
regulation of food intake in the Japanese quail. General and Comparative
Endocrinology, 141(2), 178–183. http://doi.org/10.1016/j.ygcen.2004.12.021
Shrivastava, S. R., Shrivastava, P. S., & Ramasamy, J. (2013). Role of self-care in
management of diabetes mellitus. Journal of Diabetes and Metabolic
Disorders, 12(1), 14. http://doi.org/10.1186/2251-6581-12-14
Skyler, J. S., & Sosenko, J. M. (2013). The evolution of type 1 diabetes. JAMA,
309(23), 2491–2492. http://doi.org/10.1001/jama.2013.6286
S, P. (2002). Structure and regulation of the growth hormone secretagogue receptor.
Minerva Endocrinologica, 27(4), 243–256.
Spalding, D., & Williamson, R. C. N. (2011). Pancreatic cancer. Medicine, 39(5),
274–278. http://doi.org/10.1016/j.mpmed.2011.02.011
Steiger, A., Dresler, M., Schüssler, P., & Kluge, M. (2011). Ghrelin in mental
health, sleep, memory. Molecular and Cellular Endocrinology, 340(1), 88–
96. http://doi.org/10.1016/j.mce.2011.02.013
Stengel, A., & Taché, Y. (2012). Ghrelin - a pleiotropic hormone secreted from
endocrine x/a-like cells of the stomach. Frontiers in Neuroscience, 6, 24.
http://doi.org/10.3389/fnins.2012.00024

119

Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005). Type 2 diabetes:
principles of pathogenesis and therapy. The Lancet, 365(9467), 1333–1346.
http://doi.org/10.1016/S0140-6736(05)61032-X
Sugino, T., Hasegawa, Y., Kikkawa, Y., Yamaura, J., Yamagishi, M., Kurose, Y., …
Terashima, Y. (2002). A transient ghrelin surge occurs just before feeding in
a scheduled meal-fed sheep. Biochemical and Biophysical Research
Communications, 295(2), 255–260.
Szkudelski, T. (2001). The mechanism of alloxan and streptozotocin action in B
cells of the rat pancreas. Physiological Research / Academia Scientiarum
Bohemoslovaca, 50(6), 537–546.
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011a). Management
of type 2 diabetes: new and future developments in treatment. The Lancet,
378(9786), 182–197. http://doi.org/10.1016/S0140-6736(11)60207-9
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011b). Management
of type 2 diabetes: new and future developments in treatment. The Lancet,
378(9786), 182–197. http://doi.org/10.1016/S0140-6736(11)60207-9
Takahashi, H., Kurose, Y., Kobayashi, S., Sugino, T., Kojima, M., Kangawa, K., …
Terashima, Y. (2006). Ghrelin enhances glucose-induced insulin secretion in
scheduled meal-fed sheep. The Journal of Endocrinology, 189(1), 67–75.
http://doi.org/10.1677/joe.1.06310
Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., …
Nakao, K. (2000). Ghrelin strongly stimulates growth hormone release in
humans. The Journal of Clinical Endocrinology and Metabolism, 85(12),
4908–4911. http://doi.org/10.1210/jcem.85.12.7167

120

Tan, G. D. (2008). The pancreas. Anaesthesia & Intensive Care Medicine, 9(10),
424–427. http://doi.org/10.1016/j.mpaic.2008.07.016
The Discovery of Insulin. (n.d.). Retrieved May 18, 2015, from
http://www.nobelprize.org/educational/medicine/insulin/discoveryinsulin.html
ThidarMyint, H., Yoshida, H., Ito, T., & Kuwayama, H. (2006). Dose-dependent
response of plasma ghrelin and growth hormone concentrations to bovine
ghrelin in Holstein heifers. Journal of Endocrinology, 189(3), 655–664.
http://doi.org/10.1677/joe.1.06746
Thompson, N. M., Gill, D. A. S., Davies, R., Loveridge, N., Houston, P. A.,
Robinson, I. C. A. F., & Wells, T. (2004). Ghrelin and des-octanoyl ghrelin
promote adipogenesis directly in vivo by a mechanism independent of the
type 1a growth hormone secretagogue receptor. Endocrinology, 145(1), 234–
242. http://doi.org/10.1210/en.2003-0899
Tortora, G. J., & Derrickson, B. H. (2011). Principles of Anatomy and Physiology.
Wiley.
Tóth, K., László, K., & Lénárd, L. (2010). Role of intraamygdaloid acylated-ghrelin
in spatial learning. Brain Research Bulletin, 81(1), 33–37.
http://doi.org/10.1016/j.brainresbull.2009.10.003
Tritos, N. A., Kissinger, K. V., Manning, W. J., & Danias, P. G. (2004). Association
between ghrelin and cardiovascular indexes in healthy obese and lean men.
Clinical Endocrinology, 60(1), 60–66.
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000). Ghrelin induces adiposity in
rodents. Nature, 407(6806), 908–913. http://doi.org/10.1038/35038090

121

Tschöp, M., Statnick, M. A., Suter, T. M., & Heiman, M. L. (2002). GH-releasing
peptide-2 increases fat mass in mice lacking NPY: indication for a crucial
mediating role of hypothalamic agouti-related protein. Endocrinology,
143(2), 558–568. http://doi.org/10.1210/endo.143.2.8633
Tschöp, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman,
M. L. (2001). Circulating Ghrelin Levels Are Decreased in Human Obesity.
Diabetes, 50(4), 707–709. http://doi.org/10.2337/diabetes.50.4.707
Tsui, H., Razavi, R., Chan, Y., Yantha, J., & Dosch, H.-M. (2007). “Sensing”
autoimmunity in type 1 diabetes. Trends in Molecular Medicine, 13(10),
405–413. http://doi.org/10.1016/j.molmed.2007.07.006
Turk, N., Dağistanli, F. K., Sacan, O., Yanardag, R., & Bolkent, S. (2012). Obestatin
and insulin in pancreas of newborn diabetic rats treated with exogenous
ghrelin. Acta Histochemica, 114(4), 349–357.
http://doi.org/10.1016/j.acthis.2011.07.003
Unniappan, S., & Peter, R. E. (2005). Structure, distribution and physiological
functions of ghrelin in fish. Comparative Biochemistry and Physiology. Part
A, Molecular & Integrative Physiology, 140(4), 396–408.
http://doi.org/10.1016/j.cbpb.2005.02.011
Veilleux, A., Houde, V. P., Bellmann, K., & Marette, A. (2010). Chronic inhibition
of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but
inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
Molecular Endocrinology (Baltimore, Md.), 24(4), 766–778.
http://doi.org/10.1210/me.2009-0328

122

Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011).
Pancreatic cancer. The Lancet, 378(9791), 607–620.
http://doi.org/10.1016/S0140-6736(10)62307-0
Volante, M., AllÌa, E., Gugliotta, P., Funaro, A., Broglio, F., Deghenghi, R., …
Papotti, M. (2002). Expression of Ghrelin and of the GH Secretagogue
Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. The
Journal of Clinical Endocrinology & Metabolism, 87(3), 1300–1308.
http://doi.org/10.1210/jcem.87.3.8279
Wajnrajch, M. P., Ten, I. S., Gertner, J. M., & Leibel, R. L. (2011). Genomic
Organization of the Human GHRELIN Gene. International Journal on
Disability and Human Development, 1(4), 231–234.
http://doi.org/10.1515/IJDHD.2000.1.4.231
Walker, A. K., Gong, Z., Park, W.-M., Zigman, J. M., & Sakata, I. (2013).
Expression of Serum Retinol Binding Protein and Transthyretin within
Mouse Gastric Ghrelin Cells. PloS One, 8(6), e64882.
http://doi.org/10.1371/journal.pone.0064882
Wang, Y., Nishi, M., Doi, A., Shono, T., Furukawa, Y., Shimada, T., … Nanjo, K.
(2010). Ghrelin inhibits insulin secretion through the AMPK–UCP2 pathway
in β cells. FEBS Letters, 584(8), 1503–1508.
http://doi.org/10.1016/j.febslet.2010.02.069
Warnock, G. L., Kneteman, N. M., Ryan, E., Seelis, R. E. A., Rabinovitch, A., &
Rajotte, R. V. (1991). Normoglycaemia after transplantation of freshly
isolated and cryopreserved pancreatic islets in Type 1 (insulin-dependent)
diabetes mellitus. Diabetologia, 34(1), 55–58.
http://doi.org/10.1007/BF00404026

123

Watanabe, M., Hayasaki, H., Tamayama, T., & Shimada, M. (1998). Histologic
distribution of insulin and glucagon receptors. Brazilian Journal of Medical
and Biological Research = Revista Brasileira De Pesquisas Médicas E
Biológicas / Sociedade Brasileira De Biofísica ... [et Al.], 31(2), 243–256.
Weerakiet, S., Srisombut, C., Rojanasakul, A., Panburana, P., Thakkinstian, A., &
Herabutya, Y. (2004). Prevalence of gestational diabetes mellitus and
pregnancy outcomes in Asian women with polycystic ovary syndrome.
Gynecological Endocrinology: The Official Journal of the International
Society of Gynecological Endocrinology, 19(3), 134–140.
Wells, B., DiPiro, J., Schwinghammer, T., Matzke, G., Yee, G., Posey, L. M., &
Talbert, R. L. (2008). Pharmacotherapy Handbook EBOOK. McGraw Hill
Professional.
White, R., & Sherman, C. (1999). Exercise in Diabetes Management Maximizing
Benefits, Controlling Risks. The Physician and Sportsmedicine, 27(4), 0.
http://doi.org/10.3810/psm.1999.04.787
WHO | Definition and diagnosis of diabetes mellitus and intermediate
hyperglycaemia. (n.d.). Retrieved July 31, 2014, from
http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/
Wierup, N., Yang, S., McEvilly, R. J., Mulder, H., & Sundler, F. (2004). Ghrelin is
expressed in a novel endocrine cell type in developing rat islets and inhibits
insulin secretion from INS-1 (832/13) cells. The Journal of Histochemistry
and Cytochemistry: Official Journal of the Histochemistry Society, 52(3),
301–310.

124

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of
diabetes: estimates for the year 2000 and projections for 2030. Diabetes
Care, 27(5), 1047–1053.
Wu, J. T., & Kral, J. G. (2004). Ghrelin: integrative neuroendocrine peptide in
health and disease. Annals of Surgery, 239(4), 464–474.
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999). Exendin-4
stimulates both beta-cell replication and neogenesis, resulting in increased
beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes,
48(12), 2270–2276.
Yada, T., Damdindorj, B., Rita, R. S., Kurashina, T., Ando, A., Taguchi, M., …
Dezaki, K. (2014). Ghrelin signalling in β-cells regulates insulin secretion
and blood glucose. Diabetes, Obesity & Metabolism, 16 Suppl 1, 111–117.
http://doi.org/10.1111/dom.12344
Yang, C., Liu, Z., Liu, K., & Yang, P. (2014). Mechanisms of Ghrelin anti-heart
failure: inhibition of Ang II-induced cardiomyocyte apoptosis by downregulating AT1R expression. PloS One, 9(1), e85785.
http://doi.org/10.1371/journal.pone.0085785
Yildirim, S., Sundler, F., & Bolkent, S. (2007). Ghrelin and insulin gene expression
changes in streptozotocin-induced diabetic rats after rosiglitazone
pretreatment. European Journal of Histochemistry: EJH, 51(1), 11–18.
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002). Effect of 6-week
course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity,
and β-cell function in type 2 diabetes: a parallel-group study. The Lancet,
359(9309), 824–830. http://doi.org/10.1016/S0140-6736(02)07952-7

125

Zhang, S., Zhang, Q., Zhang, L., Li, C., & Jiang, H. (2013). Expression of ghrelin
and leptin during the development of type 2 diabetes mellitus in a rat model.
Molecular Medicine Reports, 7(1), 223–228.
http://doi.org/10.3892/mmr.2012.1154
Zhao, Z., Liu, H., Xiao, K., Yu, M., Cui, L., Zhu, Q., … Zhou, Y. (2014). Ghrelin
administration enhances neurogenesis but impairs spatial learning and
memory in adult mice. Neuroscience, 257, 175–185.
http://doi.org/10.1016/j.neuroscience.2013.10.063
Zhu, Q., Xiao, K., Yu, M., Niu, M., Li, C., Gao, Y., … Zhou, Y. (2013). Ghrelin but
not nesfatin-1 affects certain forms of learning and memory in both rats and
mice. Brain Research, 1541, 42–51.
http://doi.org/10.1016/j.brainres.2013.10.022
Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., & Elmquist, J. K. (2006).
Expression of ghrelin receptor mRNA in the rat and the mouse brain. The
Journal of Comparative Neurology, 494(3), 528–548.
http://doi.org/10.1002/cne.20823
Zigman, J. M., Nakano, Y., Coppari, R., Balthasar, N., Marcus, J. N., Lee, C. E., …
Elmquist, J. K. (2005). Mice lacking ghrelin receptors resist the development
of diet-induced obesity. The Journal of Clinical Investigation, 115(12),
3564–3572. http://doi.org/10.1172/JCI26002

126

List of Publications


Conferences:
o Graduate Students Research Conference, March 22 – 24, 2015

